{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":1303,"total_is_capped":false,"direct_labels_cover":3,"predictions_cover":1303,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"query_hash":"b1cf7d12156a","filters":{"topic":"HER2/EGFR in Cancer Research"}},"results":[{"id":"W2318605753","doi":"10.1056/nejm200103153441101","title":"Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2","year":2001,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11512,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Trastuzumab; Epirubicin; Anthracycline; Internal medicine; Breast cancer; Oncology; Cyclophosphamide; Chemotherapy; Doxorubicin; Metastatic breast cancer; Paclitaxel; Cancer; Gastroenterology","retraction":null,"screen_n_in":null,"score":{"opus":0.1035786067360863,"gpt":0.4099576805019227,"spread":0.3063790737658363,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001053889,0.0002645304,0.001101472,0.0003355203,0.00005064461,0.00001955662,0.0002334631,0.00008223623,0.001127677],"category_scores_gemma":[0.0004385646,0.0001702184,0.0001978421,0.000335796,0.0002238442,0.0002181572,0.00002522861,0.0004715393,0.000001481806],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002297163,"about_ca_system_score_gemma":0.00113033,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001128081,"about_ca_topic_score_gemma":0.0001106768,"domain_scores_codex":[0.9972121,0.000110819,0.000793234,0.0002234915,0.001220991,0.0004394237],"domain_scores_gemma":[0.9971818,0.0007055916,0.0005450124,0.0003018759,0.0007113615,0.000554338],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.02924986,0.0007394481,0.125049,0.001403966,0.002198738,0.001346148,0.003724863,0.0008181735,0.1146831,0.00007175334,0.1094285,0.6112865],"study_design_scores_gemma":[0.2179659,0.006786396,0.07845744,0.01027975,0.001161291,0.009575605,0.001049772,0.002382496,0.01474953,0.0005569457,0.6564719,0.0005630027],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9542866,0.006092162,0.003903586,0.03373329,0.0006772438,0.0007884944,0.00009832004,0.00001978376,0.0004004909],"genre_scores_gemma":[0.9658299,0.02063406,0.003722304,0.002662125,0.005389899,0.00001489475,0.00002637717,0.00008570019,0.001634727],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6107234,"threshold_uncertainty_score":0.9997854,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2149908785","doi":"10.1056/nejmoa052306","title":"Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer","year":2005,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5098,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency; McGill University","funders":"","keywords":"Trastuzumab; Medicine; Breast cancer; Oncology; Chemotherapy; Adjuvant; Monoclonal antibody; Internal medicine; Adjuvant chemotherapy; Cancer; Stage (stratigraphy); Antibody; Immunology","retraction":null,"screen_n_in":null,"score":{"opus":0.01611926741677746,"gpt":0.3460186708027299,"spread":0.3298994033859524,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001029087,0.0001968168,0.0006922761,0.0003570738,0.00002122357,0.000008737885,0.000152692,0.000094805,0.004447939],"category_scores_gemma":[0.00009502105,0.0001259977,0.0000886556,0.0003301532,0.000146798,0.0001160255,0.0000159682,0.0008395786,0.00001431477],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005802396,"about_ca_system_score_gemma":0.0007310237,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007359544,"about_ca_topic_score_gemma":0.0006600738,"domain_scores_codex":[0.9977418,0.0001060042,0.0006541754,0.0001848242,0.0009270871,0.0003861446],"domain_scores_gemma":[0.9987222,0.0001088862,0.0001777487,0.0001819258,0.0002907169,0.0005184981],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.007043089,0.0002360957,0.06269674,0.0000623342,0.0001330964,0.0011045,0.004351454,0.00003782617,0.002915669,0.000008362491,0.01939628,0.9020146],"study_design_scores_gemma":[0.1114031,0.002710029,0.6978382,0.004178235,0.0001497742,0.007013271,0.0003904518,0.0001491506,0.001575368,0.0001020602,0.1742733,0.0002171056],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8134167,0.01076033,0.0001550208,0.1728565,0.0004362177,0.000306902,0.00001413573,0.00001196594,0.002042259],"genre_scores_gemma":[0.9793025,0.004123266,0.0003886745,0.00394812,0.01110412,0.000007923018,0.000002353673,0.00003704003,0.001085988],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9017975,"threshold_uncertainty_score":0.9964621,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2159967578","doi":"10.1056/nejmoa1209124","title":"Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer","year":2012,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3784,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Trastuzumab emtansine; Trastuzumab; Antibody-drug conjugate; Medicine; Cytotoxic T cell; Metastatic breast cancer; Conjugate; Breast cancer; Oncology; Antibody; Linker; Cancer research; Cancer; Monoclonal antibody; Pharmacology; Internal medicine; Immunology; In vitro; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.0357706020618461,"gpt":0.3903459424953969,"spread":0.3545753404335508,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001351905,0.0002072222,0.0007178122,0.0002349825,0.00006507075,0.000007291228,0.0001492164,0.00008896214,0.001117154],"category_scores_gemma":[0.0005590814,0.0001322288,0.0001267575,0.0002726589,0.00014941,0.0001891768,0.00001854385,0.000530211,0.000006138941],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00037443,"about_ca_system_score_gemma":0.0007732613,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001901643,"about_ca_topic_score_gemma":0.00005923289,"domain_scores_codex":[0.9977618,0.00008162382,0.0006029491,0.0001498347,0.0008456617,0.0005580746],"domain_scores_gemma":[0.997428,0.0004497044,0.0002794939,0.0001900417,0.0007106965,0.0009420339],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.008621866,0.0003098958,0.02036739,0.0003004878,0.0004013149,0.0001910611,0.003325304,0.00002438423,0.02041515,0.0001612098,0.07395464,0.8719273],"study_design_scores_gemma":[0.1905749,0.01011194,0.2107713,0.006328134,0.001197154,0.01564164,0.001439039,0.00009072843,0.00763286,0.0004077762,0.5553495,0.0004550913],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7252936,0.03972935,0.00963101,0.2109486,0.006238988,0.001868471,0.0001640764,0.00006233725,0.00606358],"genre_scores_gemma":[0.9718511,0.002040032,0.00176843,0.001390692,0.02125786,0.00001368504,0.00001150036,0.00005183685,0.001614894],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8714722,"threshold_uncertainty_score":0.999796,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2098775844","doi":"10.1056/nejmoa0910383","title":"Adjuvant Trastuzumab in HER2-Positive Breast Cancer","year":2011,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2775,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta","funders":"U.S. Army Medical Research and Development Command; National Cancer Institute; Genentech; Sanofi; Eli Lilly and Company; California Breast Cancer Research Program; GlaxoSmithKline; Amgen","keywords":"Trastuzumab; Medicine; Anthracycline; Internal medicine; Regimen; Docetaxel; Carboplatin; Breast cancer; Oncology; Cardiotoxicity; Adjuvant; Cancer; Chemotherapy; Surgery; Cisplatin","retraction":null,"screen_n_in":null,"score":{"opus":0.0562133101311759,"gpt":0.3561151897078348,"spread":0.2999018795766589,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001221812,0.000172218,0.0006821009,0.0003936283,0.00002553355,0.000004465833,0.0001846391,0.00008623733,0.003753311],"category_scores_gemma":[0.0002083367,0.0001087193,0.00007610027,0.0003622625,0.0001741624,0.0000952312,0.00002472224,0.0008607353,0.0000120432],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003495156,"about_ca_system_score_gemma":0.0008860377,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003864358,"about_ca_topic_score_gemma":0.0006298395,"domain_scores_codex":[0.9978446,0.0001339031,0.0006494033,0.0001687299,0.0008380458,0.0003653333],"domain_scores_gemma":[0.9985645,0.0001050386,0.0002131328,0.0001806952,0.0003553387,0.0005812882],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.006742071,0.0003741402,0.1764354,0.0001321616,0.0002254183,0.004684907,0.01348217,0.000007409836,0.004231422,0.00009507214,0.0224084,0.7711814],"study_design_scores_gemma":[0.0794105,0.005039817,0.874982,0.004858377,0.0002507569,0.01115966,0.00117684,0.00004774504,0.001821607,0.000538323,0.02051492,0.0001994595],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9361155,0.008374429,0.0003209205,0.03460344,0.001401176,0.000458877,0.00002148089,0.00002007256,0.01868408],"genre_scores_gemma":[0.991589,0.002112307,0.0003403463,0.0008265118,0.004402332,0.000003954023,0.00000226943,0.00002900245,0.0006943451],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.770982,"threshold_uncertainty_score":0.9971574,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4281640394","doi":"10.1056/nejmoa2203690","title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer","year":2022,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2548,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Daiichi Sankyo Europe; National Cancer Institute; First Hospital of Jilin University; West China Hospital, Sichuan University; University of California, San Francisco; Kyungpook National University; Fundació Institut de Recerca Hospital Universitari Vall d’Hebron; Peking Union Medical College; Cleveland Clinic; Samsung; Universitat de Barcelona; Seoul National University Hospital; College of Medicine, Seoul National University; Memorial Sloan-Kettering Cancer Center; Yonsei University; Chinese Academy of Medical Sciences; Tel Aviv University; Seoul National University; Jilin University; Liaoning Cancer Hospital and Institute; Sichuan University; Sun Yat-sen University; Queen Mary University of London; Cleveland Clinic Foundation; University of Ulsan; Institute of Genetics; AstraZeneca; Cancer Research Institute","keywords":"Trastuzumab; Breast cancer; Medicine; Oncology; Internal medicine; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.0217942489314834,"gpt":0.3451216111915363,"spread":0.3233273622600529,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001688593,0.0002171523,0.0008197977,0.0005470908,0.00008853035,0.000007888812,0.0002865231,0.00005516574,0.005420186],"category_scores_gemma":[0.0002611007,0.0001556874,0.00009975309,0.0008311516,0.0001172827,0.00008634453,0.00005842542,0.001337685,0.000003294654],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001117664,"about_ca_system_score_gemma":0.001416945,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002004672,"about_ca_topic_score_gemma":0.0007262593,"domain_scores_codex":[0.9967423,0.0003073007,0.0008207479,0.0002440269,0.001382096,0.0005035435],"domain_scores_gemma":[0.9983967,0.0001893469,0.0003048788,0.0002617292,0.0002487302,0.0005986206],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.007018264,0.0003561541,0.08655889,0.0001878351,0.0001604289,0.002862056,0.003568596,0.0008496847,0.007847135,0.00001219333,0.01659917,0.8739796],"study_design_scores_gemma":[0.3081553,0.01711253,0.2942676,0.00551377,0.0005570136,0.03023391,0.003790131,0.0004613597,0.001747462,0.0004780664,0.3370668,0.0006161053],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9526523,0.008107225,0.00004474179,0.03668305,0.0007008999,0.0005374925,0.0000203136,0.00002385566,0.001230076],"genre_scores_gemma":[0.9921218,0.002350164,0.0001599652,0.0009858848,0.002677353,0.00003462063,0.000009501538,0.00004855472,0.001612196],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8733635,"threshold_uncertainty_score":0.995489,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2123591186","doi":"10.1016/s1470-2045(11)70336-9","title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2358,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hôpital du Saint-Sacrement","funders":"","keywords":"Pertuzumab; Trastuzumab; Docetaxel; Medicine; Internal medicine; Clinical endpoint; Breast cancer; Oncology; Population; Chemotherapy; Clinical trial; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.06039123479763487,"gpt":0.3881995916148677,"spread":0.3278083568172329,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001226815,0.0002816015,0.001382688,0.00007187853,0.00009425821,0.00002452541,0.0003779725,0.0001664881,0.0005342118],"category_scores_gemma":[0.0001825133,0.0001635873,0.00002091085,0.0002643974,0.0007477471,0.0001424206,0.0002201352,0.0005703571,0.000004116294],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006944237,"about_ca_system_score_gemma":0.001535974,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00152276,"about_ca_topic_score_gemma":0.001932494,"domain_scores_codex":[0.9973057,0.0006045143,0.0005869674,0.0004797016,0.0003087269,0.000714398],"domain_scores_gemma":[0.9980726,0.0007802699,0.0002570654,0.0004289836,0.00018015,0.0002809792],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7835139,0.001475786,0.001224555,0.0001293732,0.0002386719,0.0003371207,0.01119351,0.000004279875,0.0008541475,0.00003390334,0.00008658748,0.2009082],"study_design_scores_gemma":[0.9200645,0.02174518,0.05239725,0.000736895,0.0001385047,0.0003295829,0.001626245,0.0002367179,0.0003105945,0.00002756332,0.002144502,0.0002424681],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9899136,0.0006241543,0.00003567335,0.001607077,0.00009459064,0.00578293,0.00009619097,0.00002580127,0.001819965],"genre_scores_gemma":[0.9948663,0.002079924,0.001020581,0.0005565817,0.0002130566,0.0009848844,0.000004298931,0.00005015329,0.0002241826],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2006657,"threshold_uncertainty_score":0.6670897,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1974685860","doi":"10.5858/arpa.2013-0953-sa","title":"Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update","year":2013,"lang":"en","type":"article","venue":"Archives of Pathology & Laboratory Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1793,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"National Cancer Institute; National Institute for Health and Care Research","keywords":"Clinical Oncology; Guideline; Human Epidermal Growth Factor Receptor 2; Medicine; Breast cancer; Clinical Practice; Oncology; Internal medicine; Cancer; Gynecology; Pathology; Family medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.1532947712403345,"gpt":0.5152501178346831,"spread":0.3619553465943486,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.00568579,0.00034913,0.002800064,0.0003626922,0.00008800121,0.000001989741,0.0004924967,0.0002363014,0.0003458737],"category_scores_gemma":[0.01569754,0.0002869982,0.0003245136,0.001244267,0.008920459,0.0001545918,0.0002407207,0.001272848,0.000004837413],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001210079,"about_ca_system_score_gemma":0.002165741,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002598291,"about_ca_topic_score_gemma":0.0001756352,"domain_scores_codex":[0.9910239,0.002432804,0.004577677,0.0008277802,0.0004726636,0.000665201],"domain_scores_gemma":[0.9821828,0.01101054,0.003388465,0.000758939,0.002223975,0.0004353137],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001183456,0.001877608,0.6272201,0.0004206244,0.0003099643,0.00008883084,0.001078047,0.000002627385,0.05261379,0.0002626434,0.06330422,0.2516381],"study_design_scores_gemma":[0.008372521,0.01088127,0.9298538,0.000751562,0.0003357405,0.0001139342,0.006649384,0.000411681,0.001176978,0.0003708027,0.04074084,0.0003415156],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8521412,0.0004288311,0.0008750385,0.139973,0.0005054806,0.00191786,0.003456158,0.00005952069,0.0006429665],"genre_scores_gemma":[0.6896255,0.003738341,0.296115,0.008851372,0.0009784298,0.0003409917,0.0002307252,0.00007944138,0.00004024247],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3026336,"threshold_uncertainty_score":0.9999582,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3156985612","doi":"10.1056/nejmoa2028485","title":"Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer","year":2021,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1543,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Vinorelbine; Metastatic breast cancer; Oncology; Breast cancer; Chemotherapy; Eribulin; Gemcitabine; Cancer; Gastroenterology; Surgery; Confidence interval","retraction":null,"screen_n_in":null,"score":{"opus":0.05153200415118789,"gpt":0.3885479570907073,"spread":0.3370159529395194,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001463287,0.0001862794,0.0008872419,0.0004051657,0.00003264281,0.0000128493,0.0001529024,0.00005865903,0.004093811],"category_scores_gemma":[0.001558627,0.0001244082,0.000100289,0.0008616087,0.0001602599,0.0001075041,0.00003321055,0.0009810838,0.000008501912],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005319994,"about_ca_system_score_gemma":0.002736952,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001729027,"about_ca_topic_score_gemma":0.001637119,"domain_scores_codex":[0.997191,0.0002863924,0.0007980595,0.0002081215,0.001139818,0.0003766839],"domain_scores_gemma":[0.9977866,0.0004539395,0.0002667424,0.0002373373,0.0006576868,0.0005977053],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.005648523,0.0003958068,0.05523645,0.0004883573,0.0006893959,0.0163837,0.005912913,0.0001159609,0.01626978,0.0002682555,0.05764778,0.8409431],"study_design_scores_gemma":[0.4266547,0.005291072,0.300932,0.01287452,0.001274195,0.05355396,0.005410085,0.0004887535,0.01203335,0.005448231,0.1754073,0.0006318215],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7577896,0.01992939,0.001017005,0.210108,0.002590699,0.0006830471,0.00006524195,0.00002818574,0.00778894],"genre_scores_gemma":[0.986863,0.00301588,0.001031516,0.001599612,0.00439097,0.000006679406,0.00000603126,0.00003500155,0.003051338],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8403112,"threshold_uncertainty_score":0.9968166,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2045324973","doi":"10.1016/s0140-6736(07)60028-2","title":"2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial","year":2007,"lang":"en","type":"article","venue":"The Lancet","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1511,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency; Institute of Cancer Research","funders":"","keywords":"Trastuzumab; Medicine; Internal medicine; Hazard ratio; Breast cancer; Oncology; Clinical endpoint; Clinical trial; Chemotherapy; Adjuvant; Cancer; Surgery; Confidence interval","retraction":null,"screen_n_in":null,"score":{"opus":0.02317066928127298,"gpt":0.3436008290136301,"spread":0.3204301597323572,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002377739,0.0001915075,0.001404468,0.0001170884,0.00003258788,0.0000142823,0.0002584889,0.000111138,0.000961168],"category_scores_gemma":[0.0001459721,0.0001169221,0.0002452647,0.0003307087,0.0001813329,0.00003704778,0.00002299583,0.0004246766,0.0000169353],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002856962,"about_ca_system_score_gemma":0.0003456219,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007980884,"about_ca_topic_score_gemma":0.0006316266,"domain_scores_codex":[0.9978175,0.000225337,0.0005415392,0.0002585997,0.0005830252,0.0005740034],"domain_scores_gemma":[0.9986821,0.0004147311,0.0001367911,0.0005004937,0.0001491743,0.0001166824],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9758505,0.0002449527,0.00637919,0.00006373886,0.0002388036,0.00005527435,0.001725097,0.00000215814,0.002792975,0.00002779669,0.00273681,0.009882736],"study_design_scores_gemma":[0.9308655,0.0005767763,0.06379215,0.0003359344,0.00008515679,0.00001435691,0.0002208981,0.0000533431,0.003066059,0.00008420611,0.0007813988,0.000124239],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9799955,0.0009269189,0.00005236355,0.008859907,0.0003468842,0.004907409,0.0001015509,0.00003181562,0.004777587],"genre_scores_gemma":[0.9950919,0.0005534944,0.00007404354,0.001290203,0.001543497,0.0006035827,0.000005976631,0.00003955813,0.0007977135],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05741296,"threshold_uncertainty_score":0.9999521,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2995808512","doi":"10.1056/nejmoa1914609","title":"Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer","year":2019,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1313,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Seattle Genetics","keywords":"Capecitabine; Trastuzumab; Metastatic breast cancer; Oncology; Medicine; Internal medicine; Breast cancer; Cancer; Colorectal cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.03135860786207033,"gpt":0.3704714722607771,"spread":0.3391128643987068,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001245723,0.0001913338,0.0007913329,0.0002437845,0.00004146555,0.00001279468,0.0001239061,0.00005147533,0.001644206],"category_scores_gemma":[0.0003240816,0.0001202175,0.00008456768,0.000209057,0.0001415088,0.00009718473,0.0000205433,0.0004585381,0.000007109278],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001848429,"about_ca_system_score_gemma":0.0007432235,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000461201,"about_ca_topic_score_gemma":0.00007674366,"domain_scores_codex":[0.9980925,0.0000895812,0.0005723202,0.0002037677,0.0007056411,0.000336142],"domain_scores_gemma":[0.9978073,0.000607042,0.0002594774,0.0001751013,0.00057783,0.0005732512],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.008041342,0.0003697205,0.05632061,0.001172027,0.001077657,0.0003421108,0.006230824,0.00003156857,0.02337299,0.000310279,0.06903319,0.8336977],"study_design_scores_gemma":[0.3396202,0.02618566,0.2827309,0.009460465,0.002439577,0.02673547,0.004117072,0.0009354264,0.003208551,0.001661549,0.3022231,0.0006820115],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9030551,0.00846918,0.0009202349,0.08323563,0.001234064,0.001137005,0.00007963588,0.00001450447,0.001854651],"genre_scores_gemma":[0.9877121,0.001558489,0.001625749,0.001266626,0.004902141,0.00001360602,0.00001100053,0.00004520888,0.002865031],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8330157,"threshold_uncertainty_score":0.9992684,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4387865238","doi":"10.1200/jco.23.02005","title":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":931,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Takeda Oncology; Genentech; Menarini Group; PharmaMar; European Society for Medical Oncology; Eisai; Seagen; Jounce Therapeutics; Clovis Oncology; Daiichi Sankyo Europe; National Cancer Institute; Calithera Biosciences; AstraZeneca; Novocure; Eisai Canada; Cholangiocarcinoma Foundation; F. Hoffmann-La Roche; Taiho Pharmaceutical; University of Texas MD Anderson Cancer Center; Puma Biotechnology; Regeneron Pharmaceuticals; European Organisation for Research and Treatment of Cancer; Mersana Therapeutics; Karyopharm Therapeutics; Exelixis; GlaxoSmithKline; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Trastuzumab; Immunohistochemistry; Clinical endpoint; Gastroenterology; Oncology; Surgery; Cancer; Breast cancer; Clinical trial","retraction":null,"screen_n_in":null,"score":{"opus":0.161277714946747,"gpt":0.5034432526818972,"spread":0.3421655377351502,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.007059278,0.0001664692,0.001700326,0.000167143,0.00009474322,0.00001287921,0.0003003432,0.0002449512,0.00004101475],"category_scores_gemma":[0.01488761,0.00009589279,0.0001704557,0.0004179098,0.0006147417,0.00009530571,0.0001790846,0.001662315,0.000003868881],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002460058,"about_ca_system_score_gemma":0.003319332,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001045484,"about_ca_topic_score_gemma":0.00005471205,"domain_scores_codex":[0.9939156,0.001115619,0.003403601,0.0003030246,0.0008799923,0.0003821166],"domain_scores_gemma":[0.9861416,0.01095005,0.001793298,0.0003393481,0.0004059618,0.0003697439],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.6577554,0.006936722,0.04236623,0.00004124009,0.0002270943,0.0005646164,0.0008850804,0.00004609078,0.0002696314,0.000002465625,0.003233599,0.2876719],"study_design_scores_gemma":[0.316135,0.06138084,0.6166926,0.001022474,0.0001291059,0.00002178515,0.0001475706,0.00007495884,0.00007253753,0.00006735818,0.004169741,0.00008599097],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9931667,0.0001142973,0.0000195375,0.005025611,0.0004087797,0.0007727908,0.00005661087,0.00001174414,0.0004239492],"genre_scores_gemma":[0.9968565,0.0002679252,0.001253203,0.0004551395,0.001068042,0.000006140217,0.0000262008,0.00002781368,0.00003901472],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5743263,"threshold_uncertainty_score":0.9934104,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2098544382","doi":"10.1093/jnci/93.24.1852","title":"Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)","year":2001,"lang":"en","type":"article","venue":"JNCI Journal of the National Cancer Institute","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":889,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Trastuzumab; SKBR3; Cell growth; Cancer research; Growth inhibition; Insulin-like growth factor; Receptor; Growth factor; Growth factor receptor; Biology; Endocrinology; Internal medicine; Chemistry; Cancer cell; Breast cancer; Medicine; Cancer; Biochemistry","retraction":null,"screen_n_in":null,"score":{"opus":0.09529036687241335,"gpt":0.3876312492150588,"spread":0.2923408823426454,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007185047,0.0001665893,0.0003163684,0.0002405983,0.0002016821,0.00005629445,0.0003470937,0.00009167373,0.000417058],"category_scores_gemma":[0.000959401,0.0001166918,0.0001401738,0.000651221,0.0001547713,0.0002971017,0.00007522987,0.0006300123,0.00001829826],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001583122,"about_ca_system_score_gemma":0.001626887,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007958608,"about_ca_topic_score_gemma":0.0002433023,"domain_scores_codex":[0.997117,0.00008299334,0.0005409529,0.0002128252,0.001762522,0.0002837002],"domain_scores_gemma":[0.9976516,0.0001159633,0.0002667742,0.000126707,0.00153373,0.0003051893],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.01444434,0.0009471534,0.1536758,0.001056692,0.001666233,0.0003594916,0.008331344,0.003453194,0.2990302,0.005384396,0.456783,0.05486818],"study_design_scores_gemma":[0.003669942,0.0004135195,0.1166978,0.001599454,0.00009634787,0.0004814916,0.0001401665,0.00003788308,0.01008917,0.001453895,0.8649762,0.0003441462],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9686438,0.00194392,0.0003551808,0.02216863,0.002400046,0.0004363162,0.00007957635,0.00001773875,0.003954779],"genre_scores_gemma":[0.9870555,0.001266963,0.003196167,0.003519731,0.002337981,0.0000204288,0.000002047042,0.00002711284,0.002574106],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4081931,"threshold_uncertainty_score":0.4758554,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2379981061","doi":"10.1016/s1470-2045(16)00163-7","title":"5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":874,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hôpital du Saint-Sacrement","funders":"European Society for Medical Oncology","keywords":"Pertuzumab; Docetaxel; Medicine; Trastuzumab; Clinical endpoint; Epirubicin; Internal medicine; Breast cancer; Oncology; Neoadjuvant therapy; Surgery; Cancer; Clinical trial","retraction":null,"screen_n_in":null,"score":{"opus":0.0391025579184239,"gpt":0.3926124320995352,"spread":0.3535098741811113,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009315777,0.0002798767,0.001670845,0.0001769845,0.00007588004,0.00002718858,0.0004592311,0.0001639564,0.001056701],"category_scores_gemma":[0.0002582013,0.0001360327,0.00006962677,0.0006935148,0.0005247497,0.0001640676,0.0002000001,0.0003573379,0.000008250068],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008623668,"about_ca_system_score_gemma":0.001230156,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001480871,"about_ca_topic_score_gemma":0.005847275,"domain_scores_codex":[0.9970102,0.0006587361,0.0006393618,0.0005272879,0.0005145281,0.0006498341],"domain_scores_gemma":[0.9975587,0.0009272776,0.0003527873,0.0005865704,0.0003523942,0.0002222523],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8043063,0.001932378,0.08080667,0.0000695026,0.001264484,0.0001275098,0.001183634,0.00002165848,0.0003105923,0.00002538348,0.0002012186,0.1097507],"study_design_scores_gemma":[0.800248,0.01009486,0.1853593,0.0004418387,0.0008347936,0.000008658558,0.000311298,0.0003504642,0.0001781489,0.000005279793,0.001948623,0.0002186547],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9919596,0.0001458379,0.00008433789,0.002201405,0.0001001314,0.004381781,0.000531972,0.00002269426,0.0005722138],"genre_scores_gemma":[0.9969116,0.0009064947,0.0004117213,0.0003556293,0.0001582687,0.0005735823,0.00002136768,0.00004527989,0.0006160266],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1095321,"threshold_uncertainty_score":0.9998565,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2140055441","doi":"10.1200/jco.2008.20.6847","title":"Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":850,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Cancer Research","funders":"F. Hoffmann-La Roche; Sanofi; AstraZeneca; Eli Lilly and Company","keywords":"Anastrozole; Medicine; Trastuzumab; Internal medicine; Metastatic breast cancer; Hazard ratio; Oncology; Breast cancer; Aromatase inhibitor; Gynecology; Cancer; Tamoxifen; Confidence interval","retraction":null,"screen_n_in":null,"score":{"opus":0.1158062761522462,"gpt":0.47668609962928,"spread":0.3608798234770338,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005398737,0.0004657961,0.004309883,0.0001463213,0.0003057697,0.000037925,0.0005020463,0.000211404,0.0002673311],"category_scores_gemma":[0.001687108,0.0002235639,0.0006249865,0.0003559278,0.0009306339,0.0001783767,0.00004351179,0.001058192,0.0000035301],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002152309,"about_ca_system_score_gemma":0.003118002,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00141474,"about_ca_topic_score_gemma":0.0004151347,"domain_scores_codex":[0.9911047,0.002771692,0.003693726,0.0005302792,0.001140434,0.0007592262],"domain_scores_gemma":[0.9754562,0.01910443,0.002965193,0.0004736556,0.001357717,0.0006428548],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8692489,0.01295217,0.0004964037,0.00000642427,0.008329374,0.0002063151,0.005314817,0.00005007728,0.001505014,0.00001492114,0.0024773,0.09939834],"study_design_scores_gemma":[0.6699985,0.2495139,0.07060336,0.0001101166,0.002884705,0.00006199613,0.004747265,0.0001297756,0.0006227593,0.00003267894,0.001104923,0.0001899796],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9707783,0.0010882,0.000495592,0.02054842,0.0006116487,0.004513542,0.001828485,0.00001522341,0.0001205743],"genre_scores_gemma":[0.9937772,0.0020087,0.00140945,0.0006137596,0.00173352,0.0002421664,0.00007686402,0.00004507213,0.00009327806],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2365618,"threshold_uncertainty_score":0.9116669,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2982411421","doi":"10.1158/1541-7786.mcr-19-0582","title":"Antibody–Drug Conjugates: A Comprehensive Review","year":2019,"lang":"en","type":"review","venue":"Molecular Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":770,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Sherbrooke","funders":"Natural Science Foundation of Jiangsu Province; National Natural Science Foundation of China","keywords":"Antibody-drug conjugate; Drug; Payload (computing); Monoclonal antibody; Cytotoxic T cell; Immunotherapy; Computational biology; Cancer immunotherapy; Cancer research; Medicine; Pharmacology; Cancer; Antibody; Chemistry; Biology; Computer science; Immunology; In vitro; Biochemistry; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.354517806902707,"gpt":0.6034749384917816,"spread":0.2489571315890746,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.002904781,0.0009875,0.005468871,0.001235438,0.0002136582,0.0001585859,0.001544175,0.0005724538,0.003784147],"category_scores_gemma":[0.0006980264,0.000796497,0.001630912,0.003533878,0.0007303553,0.00008042498,0.001113652,0.005567105,0.00583615],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002122662,"about_ca_system_score_gemma":0.01067388,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001026199,"about_ca_topic_score_gemma":0.00001498144,"domain_scores_codex":[0.9869534,0.002700349,0.001395099,0.002002971,0.004723622,0.002224542],"domain_scores_gemma":[0.9924421,0.0007543925,0.0003224023,0.003151791,0.002413729,0.0009155821],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00003630637,0.00007977643,0.00000687442,0.4735115,0.0006826464,0.001576349,0.00002435814,3.227889e-7,0.0001886329,0.00006441402,0.0506504,0.4731784],"study_design_scores_gemma":[0.0004591561,0.0001939705,0.000001376721,0.3022737,0.0009166052,0.0002095022,0.00001141986,0.00000374759,0.00005435497,0.00001394976,0.6954015,0.0004607162],"study_design_candidate":"systematic_review","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000005461467,0.9782403,0.00001747367,0.001852477,0.0004241292,0.01124028,0.0002646512,0.000110868,0.007844351],"genre_scores_gemma":[0.000002360233,0.9855567,0.0001020555,0.001689838,0.0004843862,0.002989158,0.0008456002,0.0004539089,0.007875947],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.6447511,"threshold_uncertainty_score":0.9994486,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2616596696","doi":"10.1016/s1470-2045(17)30312-1","title":"Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":656,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Cancer Institute; Genentech; GlaxoSmithKline","keywords":"Medicine; Lapatinib; Capecitabine; Trastuzumab emtansine; Taxane; Trastuzumab; Internal medicine; Oncology; Breast cancer; Interim analysis; Metastatic breast cancer; Pertuzumab; Population; Cancer; Clinical trial; Colorectal cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.1471450445887598,"gpt":0.4395473762209945,"spread":0.2924023316322347,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001381846,0.0003767898,0.00265922,0.0002218187,0.0002139076,0.00006149373,0.00096286,0.0002048342,0.0003080319],"category_scores_gemma":[0.001222085,0.0002494632,0.0001305151,0.0005893558,0.0006024683,0.0002198232,0.0002584392,0.0006432859,0.000004721359],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001919983,"about_ca_system_score_gemma":0.001750941,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.02726557,"about_ca_topic_score_gemma":0.05546609,"domain_scores_codex":[0.9959414,0.0009745749,0.0008918167,0.0007632762,0.00068285,0.0007461075],"domain_scores_gemma":[0.9955316,0.001432156,0.0008806374,0.001299061,0.0006509746,0.0002055839],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.964545,0.003029333,0.009050699,0.0000287089,0.002948453,0.0001745375,0.003082528,0.0001544666,0.0003237694,0.0000101823,0.0004710185,0.01618137],"study_design_scores_gemma":[0.7859724,0.012272,0.1976468,0.0003198659,0.001991476,0.000002157099,0.000215502,0.0009587774,0.0001361228,0.000008775104,0.0002549344,0.0002211817],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9849455,0.0001344886,0.00001642962,0.00258871,0.0003898984,0.004695588,0.0046466,0.00002457251,0.002558195],"genre_scores_gemma":[0.996963,0.0003407483,0.0004181742,0.0001232943,0.0003924428,0.0006468726,0.0007915624,0.00004514403,0.0002787554],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1885961,"threshold_uncertainty_score":0.9999958,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2101299592","doi":"10.1200/jco.2009.24.2024","title":"Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":640,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"American Society of Clinical Oncology","keywords":"Pertuzumab; Trastuzumab; Medicine; Metastatic breast cancer; Internal medicine; Oncology; Adverse effect; Breast cancer; Cancer; Clinical trial; Phases of clinical research; Loading dose","retraction":null,"screen_n_in":null,"score":{"opus":0.1176703880999536,"gpt":0.4940915774878471,"spread":0.3764211893878935,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.002145088,0.0002986382,0.002299356,0.0003396299,0.0001196056,0.00001883251,0.0002688412,0.0003430252,0.0006943983],"category_scores_gemma":[0.001115085,0.0001912593,0.0003256088,0.0002493767,0.0006548744,0.0002781674,0.00007010836,0.002338805,0.000001079243],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004381832,"about_ca_system_score_gemma":0.002986384,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001240809,"about_ca_topic_score_gemma":0.0001968207,"domain_scores_codex":[0.9948403,0.0007970532,0.002415567,0.0003954509,0.001044066,0.0005075799],"domain_scores_gemma":[0.9949994,0.001358606,0.001886903,0.0002381147,0.000937761,0.0005792216],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.3893892,0.03580938,0.2564836,0.0001730424,0.001068554,0.0002874907,0.001490457,6.277369e-7,0.003964001,0.00001282697,0.0001280745,0.3111928],"study_design_scores_gemma":[0.2802149,0.09672716,0.620207,0.0002387832,0.0001634416,0.0001141026,0.0001114601,0.000008657496,0.001800812,0.00001776745,0.0002456621,0.0001502793],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9943802,0.0001513959,0.000005743733,0.003007875,0.0006540613,0.001618854,0.0001037428,0.000009105857,0.00006907446],"genre_scores_gemma":[0.9975204,0.0003848576,0.001035235,0.0001748878,0.0007341576,0.00005255288,0.000007252855,0.00005035172,0.00004022827],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3637234,"threshold_uncertainty_score":0.9999629,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2125620887","doi":"10.1016/s1470-2045(11)70033-x","title":"Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":611,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Trastuzumab; Medicine; Internal medicine; Interim analysis; Breast cancer; Oncology; Clinical endpoint; Population; Adjuvant; Surgery; Clinical trial; Hazard ratio; Cancer; Confidence interval","retraction":null,"screen_n_in":null,"score":{"opus":0.0317431920055709,"gpt":0.327746268557953,"spread":0.2960030765523821,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004283765,0.0002167294,0.001456706,0.00008817028,0.00003144454,0.000005919117,0.0001516019,0.0001174921,0.0003424112],"category_scores_gemma":[0.00002428061,0.0001069383,0.0001395663,0.0001612541,0.0002358686,0.00003481175,0.00001457848,0.0001850021,0.000005137856],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006335611,"about_ca_system_score_gemma":0.000791151,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001222638,"about_ca_topic_score_gemma":0.001130158,"domain_scores_codex":[0.9983104,0.000286045,0.000343727,0.0002944505,0.0002965003,0.0004688609],"domain_scores_gemma":[0.9988332,0.0002947705,0.0001903247,0.0003493215,0.0002359609,0.00009641372],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9043131,0.001344048,0.08148384,0.00003032633,0.000807577,0.00001932229,0.004875528,5.714757e-7,0.00003899456,0.00001911163,0.0001194493,0.006948168],"study_design_scores_gemma":[0.7753505,0.03288162,0.1905372,0.0001137045,0.0002863608,0.000005237129,0.0001547529,0.00001144397,0.0002060692,0.00001764458,0.0003345876,0.0001008675],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9861064,0.00008037547,0.00002932383,0.001260302,0.0001222283,0.01065909,0.0001810557,0.00001831639,0.001542909],"genre_scores_gemma":[0.9924694,0.0001182288,0.0004842295,0.0002472261,0.0002929461,0.00598994,0.00001243314,0.00004739121,0.000338255],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1289625,"threshold_uncertainty_score":0.4360817,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2015918488","doi":"10.1038/modpathol.2011.198","title":"HER2 testing in gastric cancer: a practical approach","year":2012,"lang":"en","type":"article","venue":"Modern Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":596,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Trastuzumab; Immunohistochemistry; Cancer; Breast cancer; Medicine; Fluorescence in situ hybridization; Pathology; Capecitabine; Oncology; CISH; In situ hybridization; Stomach cancer; Adenocarcinoma; Metastatic breast cancer; Companion diagnostic; Internal medicine; Biology; Colorectal cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.2028628030829037,"gpt":0.4404619443020513,"spread":0.2375991412191476,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008816857,0.0001320501,0.00031362,0.0001913346,0.00003781253,0.000008221945,0.00008706413,0.0001762096,0.0001148665],"category_scores_gemma":[0.0009971251,0.0001183392,0.00003585656,0.0004227777,0.0001160761,0.00009102512,0.0001045751,0.0007090648,0.00007885096],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002939285,"about_ca_system_score_gemma":0.0003577828,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002980834,"about_ca_topic_score_gemma":0.00003196081,"domain_scores_codex":[0.9981108,0.0002070913,0.0002423142,0.0003234963,0.0002870858,0.0008291645],"domain_scores_gemma":[0.9991043,0.0001995716,0.0000505247,0.0003302522,0.00007560125,0.0002397301],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0001310478,0.0006877966,0.9137011,0.0001598068,0.00001439568,0.0005946415,0.001313002,0.00007240425,0.01213577,0.0001659777,0.001085487,0.06993859],"study_design_scores_gemma":[0.00465626,0.0009599193,0.905867,0.0002277545,0.0001241111,0.01672012,0.0004801661,0.05892719,0.001533606,0.0009204183,0.008987335,0.0005961473],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9584121,0.00216538,0.01071315,0.002306249,0.0002170959,0.0005898629,0.000007429693,0.00009556233,0.02549323],"genre_scores_gemma":[0.9708495,0.00005551098,0.02743899,0.0005497017,0.0004147441,0.0002534536,0.000006515475,0.00003714417,0.0003943942],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06934244,"threshold_uncertainty_score":0.4825732,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2768980003","doi":"10.1016/s1470-2045(17)30717-9","title":"Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":589,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta; BC Cancer Agency","funders":"National Institute for Health and Care Research; Puma Biotechnology","keywords":"Medicine; Neratinib; Trastuzumab; Internal medicine; Breast cancer; Oncology; Clinical endpoint; Placebo; Regimen; Metastatic breast cancer; Adverse effect; Cancer; Clinical trial; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.09916280515671266,"gpt":0.4624950642930083,"spread":0.3633322591362956,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003355339,0.0003146404,0.002801831,0.0004163386,0.0001791355,0.00006395772,0.0006490671,0.0002711853,0.002087531],"category_scores_gemma":[0.0002038683,0.0001940339,0.0005494572,0.0004523582,0.0006231558,0.00007957287,0.0000755382,0.0007271996,0.00001622672],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005337549,"about_ca_system_score_gemma":0.00161971,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003147928,"about_ca_topic_score_gemma":0.006042316,"domain_scores_codex":[0.9963283,0.00104408,0.0008247164,0.0005159047,0.0005807994,0.0007062287],"domain_scores_gemma":[0.9968558,0.0008126576,0.0005652141,0.001271469,0.0003128403,0.0001820085],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9646903,0.00142158,0.005973177,0.0000337782,0.002384654,0.0001748157,0.0008515592,0.0003357587,0.001191509,0.00003024781,0.0006175805,0.022295],"study_design_scores_gemma":[0.9722398,0.003379461,0.01651055,0.0001112117,0.001397625,0.00001241614,0.000111068,0.003751022,0.0008788596,0.00001810474,0.001397651,0.0001922651],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9741338,0.0007478594,0.00006236865,0.01482136,0.0003595762,0.006044703,0.0003165673,0.00002645762,0.003487291],"genre_scores_gemma":[0.991768,0.0007480829,0.0001138935,0.001213784,0.001387792,0.004362972,0.00004373377,0.00004102296,0.0003206895],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02210273,"threshold_uncertainty_score":0.9988247,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2264000214","doi":"10.1016/s1470-2045(15)00551-3","title":"Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":565,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"Puma Biotechnology","keywords":"Neratinib; Medicine; Trastuzumab; Internal medicine; Breast cancer; Oncology; Placebo; Regimen; Cancer; Metastatic breast cancer; Adjuvant therapy; Gynecology; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.04734896813518842,"gpt":0.3900358492526455,"spread":0.3426868811174571,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001490894,0.0003979465,0.001664091,0.0001802675,0.0000987517,0.00003377311,0.0003357736,0.0002344221,0.00172162],"category_scores_gemma":[0.0001066338,0.0001801955,0.0001836916,0.000253747,0.0004136075,0.00009667927,0.00004490789,0.0005783624,0.00005661805],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001028845,"about_ca_system_score_gemma":0.001560501,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004751995,"about_ca_topic_score_gemma":0.00158679,"domain_scores_codex":[0.9959418,0.001144232,0.0006656729,0.0005934307,0.0006737791,0.0009810483],"domain_scores_gemma":[0.9971665,0.001296955,0.0002734593,0.0006428206,0.000365243,0.0002550828],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9058359,0.002886599,0.01337773,0.00002556816,0.0003486877,0.00013165,0.0006484192,0.00002558789,0.0002885623,0.000006289471,0.0008952784,0.07552978],"study_design_scores_gemma":[0.9682581,0.008802828,0.01816102,0.0003324388,0.0001637703,0.00001329573,0.00004766642,0.0002232548,0.0004828948,0.000007250906,0.003252485,0.0002549246],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9699923,0.0004161376,0.00009621986,0.01531507,0.0004139863,0.01258752,0.0002594172,0.0000558643,0.0008634477],"genre_scores_gemma":[0.9871892,0.0003159998,0.0001331119,0.002805911,0.001467549,0.007566513,0.00003299761,0.00007094114,0.0004177709],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07527485,"threshold_uncertainty_score":0.9991909,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2152647863","doi":"10.1200/jco.2007.13.5467","title":"Cardiac Safety Analysis of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With or Without Trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":545,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Trastuzumab; Medicine; Ejection fraction; Heart failure; Internal medicine; Breast cancer; Cyclophosphamide; Cardiac function curve; Cardiology; Cardiotoxicity; Oncology; Paclitaxel; Cancer; Surgery; Chemotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.1113342310621078,"gpt":0.4752544723547745,"spread":0.3639202412926667,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002590841,0.0002804208,0.003697306,0.0002533825,0.00008055151,0.000008652992,0.0002510342,0.0002915282,0.0002584341],"category_scores_gemma":[0.0004613649,0.0001336293,0.0007527096,0.001007721,0.000652795,0.00009560601,0.00003461501,0.001019349,5.879976e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001200469,"about_ca_system_score_gemma":0.005149452,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.007729495,"about_ca_topic_score_gemma":0.02772309,"domain_scores_codex":[0.994202,0.001214768,0.002625054,0.0003818893,0.001008399,0.0005679351],"domain_scores_gemma":[0.9950473,0.002395836,0.001353614,0.0003398576,0.0003401695,0.0005231797],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1929038,0.002169799,0.7532604,0.00002272634,0.003701412,0.0006226674,0.0009912968,0.00009813567,0.00005026085,0.000002166662,0.001745186,0.04443214],"study_design_scores_gemma":[0.07699766,0.02204496,0.8792937,0.0001210662,0.004063047,0.0001806988,0.0004840686,0.0001209749,0.00001913991,0.00000179089,0.01653773,0.0001352037],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9886541,0.003188569,0.00002544534,0.006069997,0.000548415,0.0009791497,0.0003429806,0.000005115723,0.0001862351],"genre_scores_gemma":[0.9628022,0.03516262,0.0002486367,0.0006255523,0.0008317106,0.00007386308,0.00001478278,0.00002579569,0.0002147967],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1260333,"threshold_uncertainty_score":0.9988781,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2768649895","doi":"10.1016/s1470-2045(17)30716-7","title":"Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":529,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"Jewish General Hospital; McGill University","funders":"Johnson and Johnson; F. Hoffmann-La Roche; Eli Lilly and Company","keywords":"Pertuzumab; Medicine; Trastuzumab; Trastuzumab emtansine; Docetaxel; Oncology; Internal medicine; Breast cancer; Carboplatin; Regimen; Neoadjuvant therapy; Metastatic breast cancer; Cancer; Chemotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.09179359523436297,"gpt":0.4422125994061898,"spread":0.3504190041718268,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001228867,0.0005741048,0.002064518,0.0001499826,0.000655012,0.0002564797,0.001190343,0.0003026223,0.0005009529],"category_scores_gemma":[0.0005617111,0.0003693966,0.00008591436,0.000227672,0.001088165,0.0003036011,0.0003595215,0.001088191,0.00002045146],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002941645,"about_ca_system_score_gemma":0.002510281,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004346227,"about_ca_topic_score_gemma":0.004473965,"domain_scores_codex":[0.9957668,0.0006100551,0.0007055121,0.0009502664,0.0007471818,0.001220228],"domain_scores_gemma":[0.9964132,0.0009439858,0.0005173766,0.001321225,0.0004035954,0.0004005923],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8591858,0.003741885,0.003915283,0.0001040146,0.0004803774,0.000352574,0.002836273,0.000007521877,0.000115688,0.00003590904,0.003260805,0.1259639],"study_design_scores_gemma":[0.8948277,0.01571845,0.07896309,0.0004696586,0.0003081653,0.0001029224,0.0004230189,0.001353138,0.00006084626,0.00001735987,0.007309026,0.0004465725],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.962174,0.0004813735,0.00002469492,0.02392821,0.0007957061,0.007617556,0.000427312,0.00005918563,0.004491955],"genre_scores_gemma":[0.9933774,0.00144626,0.0004870856,0.001628005,0.001305473,0.0009572378,0.0000874663,0.000120957,0.000590126],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1255174,"threshold_uncertainty_score":0.9998758,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2059715478","doi":"10.1016/j.cell.2012.12.030","title":"Architecture and Membrane Interactions of the EGF Receptor","year":2013,"lang":"en","type":"article","venue":"Cell","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":525,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"National Cancer Institute; Canadian Institutes of Health Research; Howard Hughes Medical Institute","keywords":"Extracellular; Transmembrane protein; Biology; Transmembrane domain; Biophysics; Cell biology; Intracellular; Cell membrane; Kinase; Membrane; Biochemistry; Receptor","retraction":null,"screen_n_in":null,"score":{"opus":0.01952346414713911,"gpt":0.3043025665013322,"spread":0.2847791023541931,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0000587387,0.00004436172,0.00008552661,0.00003137734,0.00002726973,0.000007225784,0.00006855663,0.0000264973,0.002785189],"category_scores_gemma":[0.00005758802,0.00002624613,0.00003166221,0.00009406967,0.00008951218,0.00001791583,0.00004996629,0.0002305008,0.0001246709],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002117439,"about_ca_system_score_gemma":0.00004935359,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001665892,"about_ca_topic_score_gemma":0.00001652325,"domain_scores_codex":[0.9995632,0.00003017668,0.00008307344,0.00008827452,0.0001331646,0.0001021514],"domain_scores_gemma":[0.9995611,0.00006958648,0.0000229506,0.0002263794,0.00005444368,0.00006548793],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0000246305,0.00007341958,0.002969861,0.0002982932,0.00001596736,9.052983e-7,0.0008762715,0.000003674026,0.9340217,0.00001617906,0.04495725,0.0167419],"study_design_scores_gemma":[0.0005516467,0.0001124073,0.01122868,0.0001456777,0.00001923064,0.00002088833,0.0002635382,0.000089132,0.6857467,0.0001364495,0.3016267,0.00005893287],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9463348,0.0002453761,0.00001991086,0.006992002,0.0002002183,0.0003802268,0.000004698124,0.00001232093,0.0458104],"genre_scores_gemma":[0.9802866,0.00005826075,0.0004178584,0.000251302,0.0001000241,0.00002182144,0.000001648283,0.000009980336,0.01885253],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2566695,"threshold_uncertainty_score":0.9981264,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2078881615","doi":"10.1056/nejmoa054504","title":"<i>HER2</i> and Responsiveness of Breast Cancer to Adjuvant Chemotherapy","year":2006,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":508,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary; Lunenfeld-Tanenbaum Research Institute; McMaster University; Queen's University; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Anthracycline; Oncology; Breast cancer; Internal medicine; Chemotherapy; Adjuvant; Adjuvant chemotherapy; Cancer; Cancer research; Human Epidermal Growth Factor Receptor 2","retraction":null,"screen_n_in":null,"score":{"opus":0.01893375892135406,"gpt":0.3470915491465274,"spread":0.3281577902251733,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001143273,0.000137921,0.0006502356,0.0002921658,0.00002529673,0.000005193167,0.0001205473,0.00006161714,0.0005706376],"category_scores_gemma":[0.0001737995,0.0000876851,0.00005111464,0.0003241511,0.0001497228,0.00004627052,0.00002138813,0.0003105117,0.000001599858],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009771296,"about_ca_system_score_gemma":0.0005582748,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002059819,"about_ca_topic_score_gemma":0.0001684603,"domain_scores_codex":[0.9982085,0.00008810723,0.0005540847,0.000140195,0.0007759087,0.0002332617],"domain_scores_gemma":[0.9984521,0.0002024681,0.0002136797,0.0001805482,0.0005369614,0.0004143018],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.01359278,0.0001570035,0.1112704,0.0003060379,0.0001578839,0.0005137905,0.001367313,0.00006061738,0.187937,0.00009722509,0.09938434,0.5851556],"study_design_scores_gemma":[0.07098971,0.003833145,0.6174889,0.003671037,0.0001949473,0.004959335,0.0002430161,0.00002268059,0.01486547,0.0004650442,0.2830967,0.0001700336],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9099076,0.006821579,0.0002780094,0.08137783,0.0003484539,0.0002353004,0.00001302086,0.000007189432,0.001011064],"genre_scores_gemma":[0.9890909,0.002050718,0.0005391211,0.001786011,0.005175725,0.000002644843,0.000001585223,0.00002913747,0.001324124],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5849856,"threshold_uncertainty_score":0.6248082,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2080518844","doi":"10.1158/1078-0432.ccr-07-0701","title":"Human Breast Cancer Cells Selected for Resistance to Trastuzumab <i>In vivo</i> Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor Network","year":2007,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":506,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Trastuzumab; Gefitinib; Lapatinib; Erlotinib; Cancer research; Epidermal growth factor receptor; ErbB; In vivo; Epidermal growth factor; Growth factor receptor; Biology; Cancer; Receptor; Medicine; Breast cancer; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.1265625171483836,"gpt":0.4760326595411657,"spread":0.3494701423927821,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.01124786,0.000445604,0.001004069,0.0003155386,0.0006452368,0.0001664,0.0006203715,0.0004904439,0.001226262],"category_scores_gemma":[0.002103018,0.0003362303,0.0001596851,0.001564214,0.0008341739,0.000116961,0.0003695892,0.002620024,0.00002278211],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001289594,"about_ca_system_score_gemma":0.00115486,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001451196,"about_ca_topic_score_gemma":0.009862454,"domain_scores_codex":[0.9920809,0.0008688256,0.001343812,0.001578211,0.001899071,0.002229211],"domain_scores_gemma":[0.9904063,0.006104253,0.0001742863,0.0008250521,0.001234011,0.001256091],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"observational","study_design_scores_codex":[0.03018586,0.0009955278,0.1269149,0.001511749,0.0003720135,0.0001028863,0.001413442,0.00003039662,0.1842761,0.001163258,0.6370759,0.01595803],"study_design_scores_gemma":[0.01800708,0.006794556,0.4895768,0.008240636,0.0001317124,0.00002860109,0.001161182,0.0001581859,0.2839026,0.001013483,0.1890868,0.001898459],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9713251,0.001997479,0.00005551491,0.01990088,0.0005317498,0.00446675,0.0008663795,0.00006621258,0.0007899441],"genre_scores_gemma":[0.9820852,0.003660092,0.0005469645,0.002388969,0.003466727,0.0008554432,0.00001442688,0.0001683567,0.00681379],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4479891,"threshold_uncertainty_score":0.999909,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2165824128","doi":"10.1200/jco.2005.04.1764","title":"Randomized Phase III Study of Trastuzumab, Paclitaxel, and Carboplatin Compared With Trastuzumab and Paclitaxel in Women With HER-2–Overexpressing Metastatic Breast Cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":484,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University","funders":"","keywords":"Trastuzumab; Medicine; Paclitaxel; Metastatic breast cancer; Carboplatin; Oncology; Breast cancer; Internal medicine; Randomized controlled trial; Chemotherapy; Cancer; Cisplatin","retraction":null,"screen_n_in":null,"score":{"opus":0.1106490242730566,"gpt":0.4916220190092541,"spread":0.3809729947361974,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006595757,0.0002827474,0.004394566,0.0003035636,0.00005479165,0.00002709935,0.0001379938,0.0001586487,0.0001369904],"category_scores_gemma":[0.0006202633,0.0001683255,0.0001178286,0.0003368064,0.001006468,0.0001759819,0.00005056979,0.001221132,2.39146e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004737382,"about_ca_system_score_gemma":0.002197861,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002077003,"about_ca_topic_score_gemma":0.001935686,"domain_scores_codex":[0.9932927,0.001829726,0.003149078,0.0003747345,0.0008749313,0.0004787811],"domain_scores_gemma":[0.992612,0.004311817,0.001893008,0.0002245931,0.0004858478,0.000472747],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8510159,0.01315399,0.07557525,0.0002627045,0.001616954,0.001590351,0.004553001,0.0002198151,0.0005077478,0.00001215993,0.0002647236,0.05122735],"study_design_scores_gemma":[0.7610185,0.03697765,0.1893883,0.0008845881,0.0008667354,0.0009748488,0.008674904,0.0006541506,0.00002556731,0.0001348182,0.0002043644,0.0001956741],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9955129,0.001266957,0.0001016672,0.001257449,0.00008759797,0.001328279,0.00002618663,0.000007089841,0.0004118642],"genre_scores_gemma":[0.9975758,0.0003215295,0.001509266,0.0001762634,0.0002419815,0.0000804974,0.000001344497,0.00003608923,0.00005725352],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.113813,"threshold_uncertainty_score":0.6864114,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3194861850","doi":"10.3390/jpm11080808","title":"Breast Cancer Treatments: Updates and New Challenges","year":2021,"lang":"en","type":"review","venue":"Journal of Personalized Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":473,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Breast cancer; Estrogen receptor; Cancer; Immunotherapy; Oncology; Targeted therapy; Radiation therapy; Triple-negative breast cancer; Internal medicine; Epidermal growth factor receptor; Bioinformatics; Cancer research; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.2674732368484319,"gpt":0.4993552194370062,"spread":0.2318819825885742,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009738042,0.0005800609,0.004840652,0.0005967242,0.00005754263,0.00002298933,0.0002477902,0.0003603283,0.006068522],"category_scores_gemma":[0.0003322357,0.0003374289,0.0006396256,0.0004321798,0.0003550189,0.00009301974,0.00007987545,0.00123669,0.00001280026],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000803501,"about_ca_system_score_gemma":0.004382044,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001889395,"about_ca_topic_score_gemma":0.0000157287,"domain_scores_codex":[0.9961277,0.0002894251,0.001242362,0.0004516819,0.001422598,0.0004662877],"domain_scores_gemma":[0.9966068,0.0003742024,0.0009073818,0.0003761765,0.0006123541,0.001123116],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001288102,0.0001111091,0.00002017689,0.01556417,0.002391224,0.001626771,0.0005699721,2.169024e-8,0.000004405748,0.00007478909,0.03989406,0.9396145],"study_design_scores_gemma":[0.004064869,0.0006725148,0.00004344796,0.1309423,0.006689158,0.0239999,0.0004474685,5.693417e-7,8.402169e-7,0.00001917556,0.832929,0.0001908509],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000009913727,0.9770384,0.000005181877,0.0210143,0.0006193452,0.0004871701,0.00005411325,0.00001343328,0.0007581014],"genre_scores_gemma":[0.000001495787,0.9856116,0.0004209724,0.0003239612,0.005856038,0.00002634029,0.00003555215,0.0001048584,0.007619183],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9394236,"threshold_uncertainty_score":0.9999078,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2745112655","doi":"10.1007/978-1-4939-7219-7_1","title":"ErbB Receptors and Cancer","year":2017,"lang":"en","type":"review","venue":"Methods in molecular biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":431,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"ErbB; Receptor tyrosine kinase; ERBB3; ERBB4; Cancer research; Receptor; Epidermal growth factor receptor; Biology; Epidermal growth factor; Signal transduction; Neuregulin; Tyrosine kinase; Growth factor receptor; Cell biology; Biochemistry","retraction":null,"screen_n_in":null,"score":{"opus":0.3336806821133151,"gpt":0.6622974962907782,"spread":0.3286168141774631,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002565011,0.00038989,0.002471951,0.0004485259,0.00005357843,0.00002066889,0.0004132527,0.0009612399,0.0003162133],"category_scores_gemma":[0.001793797,0.0002979865,0.0002891895,0.0002327637,0.0005699458,0.00001115887,0.0002666029,0.001222083,0.00002031903],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003592336,"about_ca_system_score_gemma":0.0009485268,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002204923,"about_ca_topic_score_gemma":0.00001487095,"domain_scores_codex":[0.9953271,0.002656259,0.0005513963,0.0007911886,0.0001329266,0.0005411152],"domain_scores_gemma":[0.9981341,0.0003744875,0.0002427857,0.0009990713,0.00006454291,0.0001850363],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000008995346,0.00002183198,0.00007478434,0.00553591,0.0001330596,0.0001146091,0.0000224682,2.347597e-8,0.0001796508,0.0002921179,0.0002666978,0.9933499],"study_design_scores_gemma":[0.0002669142,0.0001394577,0.000005533586,0.01040077,0.0002966364,0.0001072887,0.000003441812,0.000002370757,0.0001279268,0.0006414335,0.9877592,0.0002489789],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[9.95926e-7,0.9770463,0.01753865,0.0002271347,0.0007480491,0.00104511,0.00002105021,0.00002257364,0.003350138],"genre_scores_gemma":[4.101683e-8,0.7582145,0.2401781,0.0001032252,0.0001608661,0.0002920371,0.00003172549,0.00006550002,0.0009539549],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9931009,"threshold_uncertainty_score":0.9999472,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2156373035","doi":"10.1021/cb500129t","title":"Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?","year":2014,"lang":"en","type":"review","venue":"ACS Chemical Biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":428,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Canadian Institutes of Health Research; Wellcome Trust","keywords":"Small molecule; Drug discovery; Kinase; Binding site; Chemistry; Stereochemistry; Active site; Plasma protein binding; Biophysics; Enzyme; Combinatorial chemistry; Biochemistry; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.1308690158421731,"gpt":0.4185566617117618,"spread":0.2876876458695887,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005711362,0.0003824263,0.002198755,0.0002217983,0.00005216236,0.00001309081,0.0003585937,0.0007671116,0.00001963404],"category_scores_gemma":[0.001367269,0.0002763142,0.0003970696,0.0004287541,0.0002533877,0.00009233845,0.0002959732,0.0006396149,0.00001631985],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002789055,"about_ca_system_score_gemma":0.0005722562,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001285705,"about_ca_topic_score_gemma":7.717849e-7,"domain_scores_codex":[0.9975631,0.0001834535,0.0008266499,0.000707325,0.0002238413,0.0004956015],"domain_scores_gemma":[0.9981434,0.000517876,0.0003560092,0.0006263692,0.0001975811,0.0001587423],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000523376,0.0005701897,0.00001876202,0.06204497,0.0004659999,0.000003752596,0.0001965659,5.713794e-7,0.05646072,0.001318549,0.01035276,0.8680438],"study_design_scores_gemma":[0.00125826,0.0006125578,4.702961e-8,0.004128956,0.0005175031,0.00001209659,0.00001221217,0.00007677382,0.0260159,0.000206247,0.9668044,0.000355047],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.003520869,0.9873563,0.002636426,0.0002624321,0.0004565541,0.004670174,0.0003689389,0.00008773866,0.0006405807],"genre_scores_gemma":[0.006112311,0.9799352,0.004656827,0.00005739399,0.001409305,0.001326955,0.00572604,0.0001345569,0.0006414516],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9564517,"threshold_uncertainty_score":0.9999689,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2994917610","doi":"10.1200/jco.19.01455","title":"NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":420,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université Laval; Centre Hospitalier de l’Université de Montréal; McGill University","funders":"National Cancer Institute; American Society of Clinical Oncology; Amgen; Pfizer; Eli Lilly and Company; Genentech","keywords":"Trastuzumab; Medicine; Oncology; Internal medicine; Breast cancer; Hazard ratio; Cyclophosphamide; Docetaxel; Chemotherapy; Immunohistochemistry; Adjuvant; Cancer; Confidence interval","retraction":null,"screen_n_in":null,"score":{"opus":0.1163470475283686,"gpt":0.5119909698977256,"spread":0.3956439223693571,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00722555,0.0003804981,0.006812479,0.0002391871,0.00007073997,0.00002858864,0.0002978554,0.0005492732,0.0006504876],"category_scores_gemma":[0.003057456,0.0001929514,0.0003261389,0.0003337946,0.001032243,0.0002051143,0.0000549136,0.002254274,0.000003207485],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009853957,"about_ca_system_score_gemma":0.01196866,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001440587,"about_ca_topic_score_gemma":0.01289879,"domain_scores_codex":[0.9932959,0.00172722,0.003084816,0.0005645449,0.0006901944,0.0006373273],"domain_scores_gemma":[0.978784,0.01636332,0.003067304,0.0002739721,0.0008435893,0.0006677805],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8663756,0.003339153,0.02394331,0.0001120742,0.001548051,0.0003793761,0.0008076338,0.00003026063,0.00006156218,0.000004762587,0.004975353,0.09842283],"study_design_scores_gemma":[0.8748463,0.1062088,0.005531505,0.0007299162,0.000787838,0.0008107586,0.000830513,0.0007684319,0.0001507918,0.00004537087,0.009049068,0.000240659],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9792491,0.0001507819,0.0003948582,0.01383623,0.0006837374,0.005272272,0.00007823658,0.00001385877,0.000320934],"genre_scores_gemma":[0.9853699,0.003677509,0.004308513,0.003983763,0.001433241,0.0003539623,0.000007446339,0.0000786366,0.0007870182],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1028696,"threshold_uncertainty_score":0.9936326,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2055235037","doi":"10.1016/s1470-2045(13)70411-x","title":"Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":386,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University Health Centre; Jewish General Hospital; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"GlaxoSmithKline","keywords":"Medicine; Lapatinib; Trastuzumab; Breast cancer; Internal medicine; Clinical endpoint; Neoadjuvant therapy; Oncology; Population; Pertuzumab; Cyclophosphamide; Chemotherapy; Surgery; Clinical trial; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.1888122349117266,"gpt":0.5311267806640083,"spread":0.3423145457522817,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002291285,0.0002651981,0.001464583,0.00007096156,0.0001871876,0.00006841885,0.0009037923,0.000193025,0.00342083],"category_scores_gemma":[0.0001515914,0.0001594262,0.00008639585,0.0002056858,0.0003740473,0.0001681933,0.0001712554,0.0004658154,0.00005667477],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003783031,"about_ca_system_score_gemma":0.001756256,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006577065,"about_ca_topic_score_gemma":0.0002330917,"domain_scores_codex":[0.9966963,0.001062556,0.0006635443,0.0004621184,0.0004041742,0.0007112891],"domain_scores_gemma":[0.997268,0.0007588344,0.000323923,0.0007664455,0.0006293235,0.0002534773],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7537297,0.006436328,0.00009198448,0.0001540822,0.0003289649,0.00001873378,0.001210447,0.000008798616,0.06695408,0.0002454347,0.02794383,0.1428776],"study_design_scores_gemma":[0.8416265,0.03362902,0.0005422068,0.0002114615,0.0000697222,0.00007815054,0.0002075896,0.00118266,0.01226596,0.0003922259,0.1095839,0.0002105746],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"protocol","genre_scores_codex":[0.5985378,0.0001055015,0.00005980228,0.0296968,0.0003528013,0.3638335,0.0003623278,0.00006158224,0.00698982],"genre_scores_gemma":[0.2191866,0.0002006208,0.001731819,0.00641992,0.002317748,0.7685046,0.00007909544,0.00009989448,0.001459712],"genre_candidate":"protocol","genre_consensus":null,"teacher_disagreement_score":0.404671,"threshold_uncertainty_score":0.9974902,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2133208325","doi":"10.1093/annonc/mdh031","title":"Randomized phase II trial of gemcitabine–cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer","year":2003,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":384,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University; Princess Margaret Cancer Centre","funders":"","keywords":"Gemcitabine; Trastuzumab; Medicine; Internal medicine; Oncology; Chemotherapy; Cisplatin; Lung cancer; Breast cancer; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.09359131375202594,"gpt":0.4696181439327916,"spread":0.3760268301807656,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002345663,0.0002467242,0.002045364,0.0003267022,0.00004310492,0.00000443191,0.0001641011,0.0002471567,0.0008382752],"category_scores_gemma":[0.0006677067,0.000170437,0.0001815515,0.000532261,0.0004549809,0.00005810249,0.00004247399,0.0004560651,0.000002925137],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001887867,"about_ca_system_score_gemma":0.003389291,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001593283,"about_ca_topic_score_gemma":0.001229789,"domain_scores_codex":[0.9969155,0.0007752118,0.0009249526,0.000387993,0.0004531819,0.0005431993],"domain_scores_gemma":[0.9976724,0.0008289859,0.0004298276,0.0003283974,0.0005461326,0.000194263],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9727659,0.005184352,0.001547661,0.0003801073,0.0003973286,0.0002053172,0.003103559,0.0000452561,0.003930291,0.00006374787,0.00193882,0.01043764],"study_design_scores_gemma":[0.9094246,0.03538929,0.0001281845,0.0005003345,0.00025997,0.00003362716,0.0004037554,0.0006179571,0.05061053,0.00002620137,0.002424401,0.0001811193],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9710367,0.0007521531,0.0002150226,0.001655688,0.0001720039,0.004030498,0.00003634911,0.00001162538,0.02208997],"genre_scores_gemma":[0.9946384,0.000904404,0.001353439,0.0004635094,0.0001227384,0.0006491442,0.0000114932,0.00004373403,0.001813069],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06334128,"threshold_uncertainty_score":0.9178526,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2019184486","doi":"10.1016/s0896-6273(00)81176-9","title":"Regulation of Neuregulin Signaling by PSD-95 Interacting with ErbB4 at CNS Synapses","year":2000,"lang":"en","type":"article","venue":"Neuron","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":382,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Neuregulin; ERBB4; Neuregulin 1; Postsynaptic density; Long-term potentiation; Synaptic plasticity; Neuroscience; Postsynaptic potential; ErbB; Cell biology; Neurotransmission; Receptor tyrosine kinase; Biology; Signal transduction; Kinase; Chemistry; Receptor; Biochemistry","retraction":null,"screen_n_in":null,"score":{"opus":0.02521958510381617,"gpt":0.3173303865495232,"spread":0.292110801445707,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001582279,0.0001016493,0.0001987779,0.00006902051,0.00003406212,0.000009829877,0.00007590822,0.00005148307,0.001720779],"category_scores_gemma":[0.0001059623,0.00008712572,0.0000313608,0.0002360749,0.00005579228,0.00007948107,0.00002253571,0.0002620378,0.00003840605],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001085293,"about_ca_system_score_gemma":0.00005424234,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001693476,"about_ca_topic_score_gemma":0.00004718372,"domain_scores_codex":[0.9988152,0.0000826235,0.0002415351,0.0002559589,0.00037273,0.0002319466],"domain_scores_gemma":[0.9993814,0.00019379,0.00006360725,0.0002401743,0.00004882898,0.0000722172],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.001696903,0.0001746664,0.0409617,0.000271611,0.00001868937,0.00009752059,0.0005343408,0.001772194,0.9000326,0.000005589792,0.009329621,0.04510456],"study_design_scores_gemma":[0.005767382,0.004058085,0.2128128,0.002829403,0.0001061058,0.0003960874,0.0002351742,0.02089962,0.6415866,0.00005188297,0.1107307,0.0005261311],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.994648,0.0001613225,0.000007860538,0.00143081,0.00004918464,0.0002591104,0.000003820798,0.00003052241,0.003409385],"genre_scores_gemma":[0.9964578,0.00006349657,0.0001433173,0.0001833357,0.00009301909,0.00001161808,0.00001516236,0.00003168485,0.003000543],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.258446,"threshold_uncertainty_score":0.9991918,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2144648936","doi":"10.1634/theoncologist.12-5-610","title":"Epidermal Growth Factor Receptor Inhibitor–Associated Cutaneous Toxicities: An Evolving Paradigm in Clinical Management","year":2007,"lang":"en","type":"review","venue":"The Oncologist","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":341,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"National Cancer Institute; BC Cancer Agency; Vrije Universiteit Amsterdam; Institut Claudius Regaud; Memorial Sloan-Kettering Cancer Center","keywords":"Medicine; Epidermal growth factor receptor; EGFR inhibitors; Cetuximab; Colorectal cancer; Toxicity; Grading (engineering); Quality of life (healthcare); Gefitinib; Cancer; Oncology; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.2509656558099983,"gpt":0.5050140510855577,"spread":0.2540483952755594,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005214107,0.0006931298,0.00323603,0.0003271105,0.0001877309,0.00010485,0.001084568,0.001173388,0.0009907439],"category_scores_gemma":[0.002596084,0.0004567489,0.0007404728,0.0009537217,0.0008560323,0.00009606191,0.0004476983,0.003440897,0.0005204474],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004655972,"about_ca_system_score_gemma":0.00116641,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004411816,"about_ca_topic_score_gemma":0.0005070983,"domain_scores_codex":[0.9920124,0.002213276,0.002396948,0.0009924154,0.001084926,0.001299964],"domain_scores_gemma":[0.9941779,0.003310145,0.0007292143,0.001174266,0.0001516111,0.000456864],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001534373,0.0008835969,0.0007536177,0.007352759,0.0004276781,0.002483862,0.0001965167,5.363864e-7,2.443877e-7,0.0001816145,0.01448052,0.9730856],"study_design_scores_gemma":[0.0009746379,0.001585707,0.000557997,0.01326998,0.0004968955,0.0002127985,0.0002312427,0.00001830358,0.000001145689,0.00008209625,0.9820623,0.0005068809],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0008544303,0.9749979,0.00001573513,0.0008178535,0.001686643,0.004815883,0.000159568,0.0002571468,0.01639481],"genre_scores_gemma":[0.001170985,0.9925544,0.0003061966,0.0006061313,0.001697763,0.0003198606,0.0002365285,0.0001561717,0.002951924],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9725788,"threshold_uncertainty_score":0.9999225,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1966937303","doi":"10.1073/pnas.1014835108","title":"Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2 <sup>+</sup> breast cancer patients","year":2011,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":332,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Research Manitoba","funders":"National Cancer Institute; Instituto de Salud Carlos III; Breast Cancer Research Foundation","keywords":"Trastuzumab; Cancer research; Cyclin D; Cyclin E; Breast cancer; Cyclin E1; Cyclin D1; Cyclin A; Cyclin; Cyclin B; Cyclin A2; Cell cycle; Cancer; Biology; Medicine; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.0794277388188846,"gpt":0.3594816967174915,"spread":0.2800539578986069,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00113615,0.000108835,0.0002452127,0.0002736259,0.00008818231,0.000007455916,0.0006891227,0.0001124441,0.000187695],"category_scores_gemma":[0.000434942,0.00007490637,0.00005927645,0.001233001,0.0006234719,0.0003042469,0.0001179111,0.0002504484,0.00000163758],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001717654,"about_ca_system_score_gemma":0.0001899399,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001336834,"about_ca_topic_score_gemma":8.59496e-7,"domain_scores_codex":[0.9968834,0.0000124813,0.0005358533,0.0003280586,0.002026872,0.0002133479],"domain_scores_gemma":[0.9985107,0.00006158713,0.0004701205,0.00002173894,0.0008722926,0.00006360697],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.001138936,0.00165312,0.4217072,0.00177153,0.00008136314,4.847231e-8,0.01267443,0.00003504739,0.4655634,0.08511712,0.007868097,0.002389675],"study_design_scores_gemma":[0.0007822682,0.0001167444,0.6144751,0.001672133,0.00001532918,0.000002428548,0.000445752,0.0005634435,0.3436615,0.03805018,0.0001134792,0.0001016482],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9889346,0.0001119453,0.000001316149,0.002734424,0.00001139851,0.0004634092,0.0001253965,0.000007610763,0.007609921],"genre_scores_gemma":[0.997821,0.0001003714,0.001501481,0.0002343604,0.00003956181,0.00004819153,2.96562e-7,0.000007918415,0.0002467693],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1927679,"threshold_uncertainty_score":0.3054593,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2162901058","doi":"10.1016/s1470-2045(15)00051-0","title":"Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":306,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Translational Research in Oncology","funders":"Novartis Pharmaceuticals Corporation","keywords":"Everolimus; Medicine; Trastuzumab; Internal medicine; Metastatic breast cancer; Breast cancer; Oncology; Response Evaluation Criteria in Solid Tumors; Paclitaxel; Placebo; Cancer; Clinical trial; Phases of clinical research; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.1072753189955495,"gpt":0.4374998133184536,"spread":0.330224494322904,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005748689,0.0003049814,0.001211539,0.00009925956,0.0001130246,0.0000143358,0.0002047997,0.0001496041,0.00007479532],"category_scores_gemma":[0.0001144201,0.0001683835,0.0001074245,0.0002730631,0.0002982128,0.00009537329,0.00003652272,0.0002469804,0.000008672566],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002357972,"about_ca_system_score_gemma":0.001936211,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001101335,"about_ca_topic_score_gemma":0.001900824,"domain_scores_codex":[0.9976958,0.0002616312,0.0004490196,0.0004166292,0.0005957697,0.0005811722],"domain_scores_gemma":[0.9972435,0.0006641244,0.0003778719,0.0004516557,0.0009928999,0.0002699285],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.956636,0.005636608,0.001340232,0.0001130174,0.0006347123,0.00002785308,0.003187894,0.0005460073,0.00002694526,0.0000484198,0.0004918771,0.03131044],"study_design_scores_gemma":[0.9290218,0.0624731,0.001024094,0.0002464417,0.0006221152,0.0000349666,0.0006053229,0.0007358648,0.000687454,0.00004291158,0.004324549,0.0001813266],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9764553,0.0002112183,0.0003019031,0.008558732,0.0003009627,0.01274836,0.0005373681,0.00004644609,0.0008397009],"genre_scores_gemma":[0.994077,0.0002305842,0.0004911964,0.0003071333,0.0005470011,0.003631137,0.00027538,0.00005668483,0.0003839034],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05683649,"threshold_uncertainty_score":0.686648,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2048686497","doi":"10.1200/jco.2003.12.109","title":"Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With Paclitaxel","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":296,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Trastuzumab; Medicine; Paclitaxel; Pharmacokinetics; Internal medicine; Adverse effect; Oncology; Metastatic breast cancer; Pharmacology; Breast cancer; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.1723146508754793,"gpt":0.5133159105305432,"spread":0.3410012596550639,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004934407,0.0001145905,0.001245799,0.0001985144,0.00001828182,0.000005268186,0.0001226096,0.0002488541,0.0001770177],"category_scores_gemma":[0.004898801,0.00008153623,0.0001429837,0.0002112363,0.0003986943,0.00006745432,0.00003018094,0.001140609,0.000003011574],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002014389,"about_ca_system_score_gemma":0.002270939,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001539789,"about_ca_topic_score_gemma":0.00009280396,"domain_scores_codex":[0.9963151,0.0006457551,0.002104535,0.0001752303,0.0005280122,0.000231376],"domain_scores_gemma":[0.9947877,0.003306376,0.0009640802,0.0001632512,0.0004501076,0.0003284669],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.03610431,0.00805772,0.5327986,0.0002405228,0.0004635715,0.001243983,0.0003025544,0.00002954982,0.0005562206,0.0008242468,0.001842786,0.4175359],"study_design_scores_gemma":[0.04647345,0.04615868,0.8598821,0.0003675385,0.0002187921,0.0005870896,0.0001442009,0.000113756,0.0003577825,0.0006376578,0.04495467,0.0001042893],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9850538,0.0007278926,0.0003799605,0.006435519,0.0004352597,0.000374116,0.000003208208,0.000003798512,0.006586496],"genre_scores_gemma":[0.9953814,0.001287021,0.002532978,0.0004534347,0.00017995,0.000002092042,0.000001110798,0.00001701566,0.0001449669],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4174316,"threshold_uncertainty_score":0.5864676,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2948726637","doi":"10.1016/s0140-6736(19)30650-6","title":"6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial","year":2019,"lang":"en","type":"article","venue":"The Lancet","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":283,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Health Economics","funders":"Health Technology Assessment Programme; National Institute for Health and Care Research; University of Warwick; Cancer Research UK; University of Cambridge; Department of Health and Social Care","keywords":"Medicine; Trastuzumab; Breast cancer; Clinical endpoint; Internal medicine; Intention-to-treat analysis; Surgery; Randomized controlled trial; Clinical trial; Chemotherapy; Adjuvant; Cancer; Oncology","retraction":null,"screen_n_in":null,"score":{"opus":0.05371163214208088,"gpt":0.3732203289132454,"spread":0.3195086967711646,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001432073,0.0002316288,0.001284966,0.00007627533,0.00005693538,0.00001756962,0.0005445413,0.0001010336,0.0002365052],"category_scores_gemma":[0.0006811037,0.0001603587,0.0003372109,0.0002170345,0.0002574572,0.00007567597,0.0001061741,0.0003245739,0.00001493041],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002206082,"about_ca_system_score_gemma":0.0008552353,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003199551,"about_ca_topic_score_gemma":0.0003438628,"domain_scores_codex":[0.9974186,0.0002354852,0.000579723,0.0003891877,0.0008423572,0.0005346771],"domain_scores_gemma":[0.996875,0.000983323,0.0002712002,0.001271246,0.0003689954,0.0002302564],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9797739,0.0005680963,0.002191689,0.0003846337,0.0004513678,0.00001090373,0.001381684,0.00001769949,0.004968294,0.00004573402,0.007070489,0.003135445],"study_design_scores_gemma":[0.9428493,0.004190405,0.0463495,0.0005221438,0.0004230879,0.000001528035,0.0004133355,0.000713841,0.003359855,0.00006540883,0.0009003314,0.0002112252],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9763303,0.0002257549,0.0000423961,0.003456001,0.001089358,0.005517579,0.0102356,0.00003190494,0.003071119],"genre_scores_gemma":[0.9971461,0.0001899343,0.0001322903,0.00006139255,0.001587036,0.000340791,0.00008101645,0.00004715267,0.0004142465],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04415781,"threshold_uncertainty_score":0.6539239,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2774227900","doi":"10.1016/j.ejca.2017.10.021","title":"Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer","year":2017,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":283,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"F. Hoffmann-La Roche; Roche","keywords":"Pertuzumab; Anthracycline; Trastuzumab; Medicine; Oncology; Internal medicine; Chemotherapy; Cancer; Breast cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.02363119783183756,"gpt":0.3797801121478566,"spread":0.356148914316019,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002932904,0.0003779013,0.001651593,0.0003422575,0.0005803299,0.0001261701,0.0005458033,0.00004772126,0.0001085092],"category_scores_gemma":[0.0004384793,0.0002377097,0.0002901438,0.0003942178,0.0006151546,0.0003065167,0.0002615075,0.0007698683,1.628172e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006893111,"about_ca_system_score_gemma":0.0008224472,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006312401,"about_ca_topic_score_gemma":0.0004534345,"domain_scores_codex":[0.9954165,0.0009722508,0.001164802,0.0004866115,0.001504737,0.0004551047],"domain_scores_gemma":[0.9959635,0.0002571979,0.001538716,0.0008692293,0.001065003,0.0003063448],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0806468,0.0006203529,0.6994997,0.00004876893,0.003111351,0.0001579506,0.008824017,0.0002534033,0.0004017852,2.874376e-7,0.00003087272,0.2064047],"study_design_scores_gemma":[0.1508611,0.00690232,0.8369601,0.001724548,0.002326074,0.00001853522,0.0004957706,0.0002483084,0.0002265923,4.888959e-7,0.00002513422,0.0002110326],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9930708,0.002802335,0.00005407252,0.001784752,0.0002028187,0.001577295,0.0003471153,0.000007642526,0.00015312],"genre_scores_gemma":[0.9975265,0.001786866,0.0001041864,0.00009144741,0.0003052286,0.00001489056,0.000004198244,0.00008525248,0.00008139956],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2061937,"threshold_uncertainty_score":0.969352,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2012505736","doi":"10.1038/modpathol.2013.103","title":"HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity","year":2013,"lang":"en","type":"review","venue":"Modern Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":282,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto","funders":"National Institute for Health and Care Research","keywords":"Polysomy; Trastuzumab; Breast cancer; Genetic heterogeneity; Fluorescence in situ hybridization; Chromosome 17 (human); Cancer; Biology; Oncology; Pathology; Internal medicine; Chromosome; Medicine; Genetics; Phenotype; Gene","retraction":null,"screen_n_in":null,"score":{"opus":0.1485677386235298,"gpt":0.48226546491079,"spread":0.3336977262872602,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004861512,0.0002636797,0.001816472,0.0003964571,0.00001988286,0.000008622415,0.0002140312,0.0005202153,0.0000547041],"category_scores_gemma":[0.0000868833,0.0002338211,0.0001666448,0.0003417965,0.0002742657,0.00003117294,0.000182144,0.0006958463,0.00001676281],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002671281,"about_ca_system_score_gemma":0.0008167329,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004405216,"about_ca_topic_score_gemma":0.00115079,"domain_scores_codex":[0.9969196,0.0006200631,0.001196349,0.0007001208,0.0001727377,0.000391091],"domain_scores_gemma":[0.9985589,0.0001759133,0.0002961187,0.0006931928,0.0001183812,0.0001575091],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.00001309928,0.0001687956,0.08918157,0.003767342,0.0000306477,0.00009655226,0.00003985294,0.000004513498,0.0001102867,0.000007740407,0.0001437699,0.9064358],"study_design_scores_gemma":[0.002968984,0.0004418463,0.8503621,0.01174313,0.000724968,0.005167658,0.00001024805,0.000421098,0.0000326423,0.0005916957,0.1267407,0.0007949815],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.05703406,0.9399823,0.0002511252,0.0007767436,0.00008040815,0.001562252,0.0001725347,0.00001575807,0.0001248248],"genre_scores_gemma":[0.02367755,0.9747519,0.0004049107,0.0001247186,0.0001270089,0.0007173411,0.00008361251,0.00005521908,0.00005767362],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9056408,"threshold_uncertainty_score":0.9534948,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2158179945","doi":"10.1016/s1470-2045(03)01137-9","title":"Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer","year":2003,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":281,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; Queen's University; University Health Network; University of Toronto","funders":"Cancer Research Society; American Association for Cancer Research","keywords":"Erlotinib; Gefitinib; Cetuximab; Epidermal growth factor receptor; Medicine; Lung cancer; Amphiregulin; Cancer research; Epidermal growth factor; Tyrosine kinase; Cancer; Carcinogenesis; Trastuzumab; Oncology; Receptor; Internal medicine; Colorectal cancer; Breast cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.3917200543381659,"gpt":0.5739504872546254,"spread":0.1822304329164595,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.01514349,0.0006008121,0.00895162,0.0004333087,0.00008685899,0.000009156713,0.00122282,0.0009977088,0.001272511],"category_scores_gemma":[0.002829869,0.0003285006,0.0008824637,0.001758713,0.001255606,0.00003049427,0.0003149608,0.004996294,0.00009774208],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001144092,"about_ca_system_score_gemma":0.01195771,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005597971,"about_ca_topic_score_gemma":0.0001393926,"domain_scores_codex":[0.9857845,0.007721724,0.002814233,0.0009705826,0.001462743,0.00124616],"domain_scores_gemma":[0.9877647,0.006816526,0.001685689,0.002020697,0.001328739,0.0003836151],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0005493076,0.000577866,0.0009038722,0.325519,0.0005920468,0.0001074806,0.0001100194,1.225198e-7,0.000002208888,0.00009181129,0.1615595,0.5099868],"study_design_scores_gemma":[0.001717922,0.003195959,0.00003338765,0.2231989,0.000964565,0.0000662009,0.00001892298,0.000001100088,0.00005987833,0.00001539538,0.7705081,0.0002196572],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001363858,0.9621376,0.000003794673,0.004740069,0.0007569811,0.00595047,0.0001297457,0.0000251717,0.02611972],"genre_scores_gemma":[0.00004236251,0.9928949,0.0005066438,0.0009603435,0.002419663,0.001492574,0.0000289935,0.0001614794,0.001493064],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.6089486,"threshold_uncertainty_score":0.9999167,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2071130163","doi":"10.1097/01.mp.0000052102.90815.82","title":"Current Perspectives on HER2 Testing: A Review of National Testing Guidelines","year":2003,"lang":"en","type":"review","venue":"Modern Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":269,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Sunnybrook Health Science Centre; Women's College Hospital; University of Toronto","funders":"","keywords":"Medicine; Medical physics; Quality assurance; Trastuzumab; Pathology; Test (biology); Fish <Actinopterygii>; External quality assessment; Intensive care medicine; Internal medicine; Breast cancer; Cancer; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.5663146011887417,"gpt":0.5638883755037888,"spread":0.002426225684952876,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002179524,0.0004923283,0.00260078,0.0004137178,0.00006151669,0.000008539159,0.0003230245,0.0002998696,0.0001571127],"category_scores_gemma":[0.02439328,0.000382747,0.0004260402,0.0008422483,0.0002292459,0.00002345816,0.0001265485,0.001136888,0.0001148781],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000589016,"about_ca_system_score_gemma":0.00320684,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000007846818,"about_ca_topic_score_gemma":8.497561e-7,"domain_scores_codex":[0.9955535,0.0006369342,0.001398888,0.0009248111,0.00100719,0.000478674],"domain_scores_gemma":[0.9944148,0.00104731,0.0006678788,0.0006995932,0.003010923,0.0001594934],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000004308793,0.0001915108,0.00003416441,0.1453153,0.00004813894,0.0001173142,0.00005646962,0.000001593994,0.000003527164,0.0001419519,0.005407201,0.8486785],"study_design_scores_gemma":[0.0002056652,0.0003604832,0.000008503651,0.2587115,0.0002927896,0.001230147,0.000008955059,0.00006495525,7.18178e-7,0.0002487159,0.7386353,0.0002322155],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000002897517,0.9866704,0.0001731025,0.0002826513,0.0002451117,0.001514112,0.00009527697,0.00006161295,0.01095482],"genre_scores_gemma":[0.000002898704,0.9913377,0.006791423,0.0004766724,0.0005038563,0.0003815426,0.00007216595,0.0001027566,0.0003309893],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.8484462,"threshold_uncertainty_score":0.9998624,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2163167967","doi":"10.1136/jclinpath-2014-202571","title":"Updated UK Recommendations for HER2 assessment in breast cancer","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":259,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Cancer Research; Ontario Institute for Cancer Research","funders":"","keywords":"Breast cancer; Medicine; Bioinformatics; Oncology; Medical physics; Cancer; Internal medicine; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.1850342865328451,"gpt":0.5861699026089259,"spread":0.4011356160760807,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005758083,0.00009029715,0.0007127333,0.0001738585,0.00003041927,0.000009488323,0.0001653501,0.0002078165,0.001171099],"category_scores_gemma":[0.001222388,0.00006879479,0.0002218557,0.000160712,0.0001217719,0.00004740497,0.00004128167,0.00109634,0.00001109677],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001466471,"about_ca_system_score_gemma":0.0008137444,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002880168,"about_ca_topic_score_gemma":0.00008555206,"domain_scores_codex":[0.9972587,0.000541294,0.001498449,0.0001819568,0.00024396,0.0002756517],"domain_scores_gemma":[0.9974541,0.001088861,0.000488079,0.0002114951,0.0005200309,0.0002374064],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00116793,0.0007685304,0.69315,0.00005579709,0.00009113592,0.0001705949,0.00005379666,0.00002910062,0.0005979498,0.000528876,0.1192707,0.1841156],"study_design_scores_gemma":[0.006499833,0.001758544,0.8068628,0.0002190244,0.00007527439,0.0006537225,0.00006094899,0.0006302654,0.00003362231,0.001684838,0.1814318,0.00008935873],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.6765222,0.0001260882,0.004770312,0.3127813,0.002728187,0.0004996629,0.00006483872,0.00001278354,0.002494607],"genre_scores_gemma":[0.9793003,0.0006895268,0.01275447,0.005289254,0.00156204,0.00003075684,0.00001362305,0.00002245385,0.0003375734],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3074921,"threshold_uncertainty_score":0.999742,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1988557714","doi":"10.1016/j.ctrv.2003.10.002","title":"Epidermal growth factor receptor: a promising target in solid tumours","year":2003,"lang":"en","type":"review","venue":"Cancer Treatment Reviews","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":254,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Epidermal growth factor receptor; Monoclonal antibody; Tyrosine kinase; Cancer research; Cancer; Receptor tyrosine kinase; Signal transduction; Targeted therapy; EGFR inhibitors; Cetuximab; Blockade; Pharmacology; Receptor; Immunology; Antibody; Internal medicine; Biology; Cell biology","retraction":null,"screen_n_in":null,"score":{"opus":0.2218575342477881,"gpt":0.4851877966864617,"spread":0.2633302624386736,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.000790698,0.001349577,0.007459244,0.0005395356,0.00009866651,0.00006892691,0.0003694707,0.000513508,0.003916231],"category_scores_gemma":[0.0002753176,0.0008836304,0.001610792,0.001137388,0.0001342632,0.0001192501,0.00007191265,0.0009851505,0.001062525],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.009079195,"about_ca_system_score_gemma":0.004091311,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004139974,"about_ca_topic_score_gemma":0.00008933489,"domain_scores_codex":[0.9932879,0.001267238,0.002140364,0.001423238,0.0005969771,0.001284344],"domain_scores_gemma":[0.9971007,0.0001809183,0.0007959245,0.001167856,0.0001266059,0.0006280295],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00002014348,0.000332472,0.0008249507,0.04519694,0.0002756271,0.0001690385,0.0001260003,1.348701e-7,0.000002645503,0.000009127849,0.01052856,0.9425144],"study_design_scores_gemma":[0.001075646,0.0003924149,0.00001747315,0.08023968,0.001015755,0.00009540491,0.000006099575,8.409235e-7,0.00003937689,0.000007022225,0.9165167,0.000593631],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00001035357,0.9832271,0.000005201561,0.0002506722,0.0006892885,0.0109526,0.0002553012,0.00006665038,0.004542847],"genre_scores_gemma":[0.000001971731,0.982815,0.001100052,0.0002211349,0.0007580787,0.009762565,0.0003563224,0.0002449556,0.004739876],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9419207,"threshold_uncertainty_score":0.9999255,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2013797830","doi":"10.1186/bcr2904","title":"Luminal-B breast cancer and novel therapeutic targets","year":2011,"lang":"en","type":"review","venue":"Breast Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":249,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Breast cancer; Surgical oncology; Estrogen receptor; Medicine; Cancer research; Gene expression profiling; Bioinformatics; Pathological; Endocrine system; Oncology; Cancer; Internal medicine; Gene; Gene expression; Biology; Hormone; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.289696687158721,"gpt":0.5148012716975511,"spread":0.2251045845388301,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002817158,0.001052014,0.003056848,0.001449261,0.0004691933,0.0002151341,0.001184573,0.0009408694,0.009073609],"category_scores_gemma":[0.00007648634,0.0008072461,0.0005897849,0.002276122,0.001475065,0.0001951918,0.0009284308,0.004512765,0.00048948],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00279226,"about_ca_system_score_gemma":0.01039704,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01711143,"about_ca_topic_score_gemma":0.0008975865,"domain_scores_codex":[0.990891,0.0006373692,0.001041539,0.001999149,0.002738333,0.002692634],"domain_scores_gemma":[0.9944687,0.0004215472,0.0002763842,0.001703688,0.001651245,0.001478372],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0004041017,0.0003284155,0.0004892402,0.03598611,0.0008816942,0.0001506144,0.0001806792,8.316776e-8,0.00002438142,0.0003271879,0.01190914,0.9493183],"study_design_scores_gemma":[0.001178095,0.000166385,0.003242844,0.03280868,0.0007677325,0.004235284,0.00006832238,0.000008451707,0.000006369632,0.00005492904,0.9567365,0.0007264026],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00001763823,0.9860907,0.00001059733,0.002468724,0.0006104808,0.003727945,0.003474423,0.0001178151,0.003481665],"genre_scores_gemma":[0.000220376,0.9806761,0.00005876616,0.0002041811,0.003490369,0.004708198,0.00010183,0.0004624577,0.01007777],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9485919,"threshold_uncertainty_score":0.9994379,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2948405934","doi":"10.1200/jco.19.00882","title":"Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":248,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Cancer Institute; American Society of Clinical Oncology","keywords":"Pertuzumab; Medicine; Trastuzumab emtansine; Internal medicine; Hazard ratio; Trastuzumab; Oncology; Breast cancer; Docetaxel; Adverse effect; Cancer; Surgery; Confidence interval","retraction":null,"screen_n_in":null,"score":{"opus":0.1404453096150034,"gpt":0.5111550693327782,"spread":0.3707097597177748,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003426176,0.0002881139,0.002593564,0.000157617,0.00009529421,0.00003010936,0.0004017806,0.0003314684,0.002792862],"category_scores_gemma":[0.002354202,0.0001661288,0.000360578,0.0002320464,0.0003952222,0.0001638598,0.0001707346,0.002491365,0.00002720403],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007087806,"about_ca_system_score_gemma":0.002322847,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002956511,"about_ca_topic_score_gemma":0.0031674,"domain_scores_codex":[0.9942998,0.001146241,0.002755967,0.0004515611,0.0008649754,0.0004815139],"domain_scores_gemma":[0.9911066,0.006241063,0.001151577,0.0003616072,0.0006350722,0.0005040332],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.009358034,0.004553228,0.8904425,0.00002162939,0.0006607369,0.0007737456,0.001058168,0.000001972256,0.0004905828,0.00002014131,0.00215957,0.09045967],"study_design_scores_gemma":[0.04718569,0.01901218,0.9301007,0.000221659,0.0002506569,0.0001361813,0.001363777,0.00008005986,0.00003176516,0.00007322067,0.00138652,0.0001576362],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9634323,0.0004641885,0.00001958904,0.03340045,0.001040608,0.001081827,0.0001749524,0.00001132262,0.0003747841],"genre_scores_gemma":[0.9958166,0.0005235019,0.0002036359,0.001643895,0.001567563,0.00001644173,0.00000855366,0.00004088661,0.0001789339],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09030204,"threshold_uncertainty_score":0.9998099,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2556607246","doi":"10.5858/arpa.2016-0331-cp","title":"HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology","year":2016,"lang":"en","type":"article","venue":"Archives of Pathology & Laboratory Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":246,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Guideline; Clinical Oncology; Internal medicine; Adenocarcinoma; Biomarker; Clinical pathology; Oncology; Pathology; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.1289693971999853,"gpt":0.4916737082039777,"spread":0.3627043110039924,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.01218737,0.0004241397,0.00372298,0.0001642732,0.0001021836,0.000002398808,0.0005421095,0.000311816,0.00001621625],"category_scores_gemma":[0.02150605,0.000257236,0.0005524485,0.00085637,0.03919664,0.00005536826,0.0006102401,0.001259568,7.066068e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007007679,"about_ca_system_score_gemma":0.001419635,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003782375,"about_ca_topic_score_gemma":0.0003294231,"domain_scores_codex":[0.9899517,0.002845579,0.004658776,0.001291301,0.0005072742,0.0007454068],"domain_scores_gemma":[0.9442105,0.05078294,0.002919839,0.001045604,0.0006372222,0.0004039339],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001992437,0.0004192155,0.6711892,0.00006563627,0.0001646923,0.0003093026,0.0005455489,3.593169e-7,0.004143559,0.0000298702,0.003374159,0.317766],"study_design_scores_gemma":[0.00876329,0.01795932,0.9639792,0.0007545691,0.0003682172,0.0001510299,0.005177975,0.0004186603,0.00007095744,0.0005280228,0.001646559,0.0001822022],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9807509,0.002416251,0.004416013,0.009933052,0.0002641313,0.001015163,0.00112988,0.00003361133,0.00004103386],"genre_scores_gemma":[0.779767,0.006822281,0.2092766,0.003288343,0.000719813,0.00004650904,0.00001904171,0.00005259483,0.000007766879],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3175838,"threshold_uncertainty_score":0.999988,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2091242368","doi":"10.1172/jci57100","title":"Breast cancer — one term, many entities?","year":2011,"lang":"en","type":"review","venue":"Journal of Clinical Investigation","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":230,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University; McGill University Health Centre","funders":"McGill University Health Centre; McGill University","keywords":"Breast cancer; Cancer; Breast tumor; Disease; Computational biology; Bioinformatics; Medicine; Tumor heterogeneity; Biology; Cancer research; Pathology; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.4923396356444193,"gpt":0.5576649504711761,"spread":0.06532531482675685,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003852396,0.0003254609,0.003238793,0.0003924124,0.00004904919,0.00005402427,0.0004371571,0.0007481899,0.001967158],"category_scores_gemma":[0.001239153,0.0002359389,0.001362264,0.0003788966,0.0005203221,0.0002124389,0.00009528938,0.002894221,0.0001907937],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003800397,"about_ca_system_score_gemma":0.005257066,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005452657,"about_ca_topic_score_gemma":0.000009096912,"domain_scores_codex":[0.9936466,0.0007209376,0.003961255,0.0003260744,0.00100589,0.0003392359],"domain_scores_gemma":[0.9938841,0.0006151853,0.003200418,0.0004680142,0.0009370921,0.0008952058],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00008333334,0.0001802577,0.002485088,0.01348101,0.0006351708,0.00008628201,0.0000375437,7.27137e-8,0.000001113933,0.0001898431,0.0163384,0.9664819],"study_design_scores_gemma":[0.0008306017,0.0004880415,0.005417977,0.07351726,0.002561336,0.0009940295,0.00000626945,0.000003160471,0.000003971196,0.0005648551,0.9153983,0.0002141975],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0003236393,0.9944799,0.00002773357,0.00117365,0.001960803,0.0005799041,0.00005918762,0.00001837918,0.001376809],"genre_scores_gemma":[0.00004250942,0.9896709,0.0009831282,0.0004638192,0.006312129,0.00003099825,0.00002552897,0.00008004891,0.002390907],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9662677,"threshold_uncertainty_score":0.9994062,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2277879584","doi":"10.1007/s40259-016-0162-9","title":"Trastuzumab in the Treatment of Breast Cancer","year":2016,"lang":"en","type":"review","venue":"BioDrugs","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":230,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Norwegian Institute of Public Health; Direktorat Jenderal Pendidikan Tinggi; Sanofi Pasteur; Johns Hopkins Bloomberg School of Public Health; University of Illinois at Urbana-Champaign; National Institutes of Health; Seqirus; Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja; Ministero della Salute; National Health and Medical Research Council; AstraZeneca; Amarin Corporation; Bundesministerium für Bildung und Forschung; Novavax; Sanofi; Comunidad de Madrid; Boston Scientific Corporation; Public Health England; University of Calgary; Arizona State University; GlaxoSmithKline; Bristol-Myers Squibb; Australian Government; Pfizer; Lembaga Pengelola Dana Pendidikan; Johns Hopkins University; Edwards Lifesciences; Bill and Melinda Gates Foundation; Instituto de Salud Carlos III; Amgen; Damon Runyon Cancer Research Foundation; Medical Research Council; Teva Pharmaceutical Industries; South African Medical Research Council; Seoul National University; U.S. Department of Veterans Affairs; Genentech; U.S. Environmental Protection Agency","keywords":"Trastuzumab; Pertuzumab; Medicine; Lapatinib; Breast cancer; Cardiotoxicity; Cancer; Disease; Oncology; Targeted therapy; Internal medicine; Pharmacology; Chemotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.1386676677073322,"gpt":0.4761857603569551,"spread":0.337518092649623,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002709988,0.000286609,0.00133965,0.0002082659,0.00002051484,0.000009270268,0.0002733549,0.0001937033,0.0009609775],"category_scores_gemma":[0.00001375853,0.0001211273,0.0004157675,0.0003961801,0.0001363078,0.00001516205,0.00001839126,0.0001755761,0.000181515],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001176393,"about_ca_system_score_gemma":0.001498315,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008009699,"about_ca_topic_score_gemma":0.0000817705,"domain_scores_codex":[0.9982003,0.0001948761,0.0004685401,0.0003194583,0.000474715,0.0003420959],"domain_scores_gemma":[0.9988558,0.0002162451,0.0001409006,0.0006444168,0.00005677595,0.00008586198],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00002427761,0.0002928599,0.00006555648,0.00612644,0.0001238975,0.00004234898,0.0002972211,3.522457e-9,0.000001443212,0.00001872783,0.0027339,0.9902733],"study_design_scores_gemma":[0.00065193,0.0002782591,0.0002536422,0.01918188,0.0002885461,0.0001066575,0.00003434062,1.205675e-7,0.000005437065,0.000003411,0.9790844,0.0001113181],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00004060407,0.9943005,4.127287e-7,0.0009333187,0.0001642857,0.00155378,0.0006801721,0.00001205815,0.002314832],"genre_scores_gemma":[0.00008853808,0.9966168,0.0000101897,0.00003887924,0.0005385281,0.0007628117,0.00002769195,0.00004010699,0.00187644],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.990162,"threshold_uncertainty_score":0.9999523,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}